header logo image


Page 3«..2345..»

Archive for the ‘Stem Cell Panama’ Category

Exosome Therapeutic Market 2020-2026 Industry Report : Size, Growth, Trends, Share, Revenue || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer…

Monday, August 17th, 2020

This Exosome Therapeutic Market Report insights will guide for an actionable ideas, better decision-making and better business strategies. Competitive landscape underlines the strategic profiling of key players in the market, comprehensively analyzing their core competencies, & strategies. Exosome Therapeutic Market report also analyzes the market status, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors & Porters Five Forces Analysis.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

More here:
Exosome Therapeutic Market 2020-2026 Industry Report : Size, Growth, Trends, Share, Revenue || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer...

Read More...

R3 International Now Offering Stem Cell Therapy Program for Crohns Disease, IBD and Ulcerative Colitis – PR Web

Friday, July 10th, 2020

Stem Cell Therapy for Crohns Disease and IBD in Mexico (888) 988-0515

SAN DIEGO (PRWEB) July 08, 2020

R3 International is now offering effective stem cell therapy for Crohns disease, Ulcerative Colitis and IBD with a new program in Mexico. The new program provides up to 200 million stem cells for patients, with treatment starting at only $2975.

Millions of individuals worldwide suffer from chronic abdominal issues that affect every aspect of daily life and lead to difficulty with functioning. Traditional treatments are often insufficient and entail significant side effects.

According to R3 CEO David Greene, MD, MBA, "Stem cell therapy for Crohns, UC and IBD is not only safe and effective, but you don't have the bad side effects like you do with traditional drugs. We've been very successful in Mexico because the therapies are not only clinically and cost effective, but we offer very high numbers of stem cells for pricing exponentially less than the US, Panama or others!"

Studies on stem cell therapy for inflammatory diseases such as Crohns are showing that they are highly effective at regulating one's immune response (Nat Rev Nephrol 2018). This typically helps reduce flare ups and pain in patients, helping to increase quality of life tremendously.

Since R3 Stem Cell International opened in Tijuana, outcomes for these inflammatory conditions have been tremendous, with patients receiving anywhere from 30 million to 200 million stem cells.

The cells offered at R3 International come from a lab with a perfect safety record and quality assurance standards that exceed those of the FDA. No preservative is necessary, so the cell viability for the biologic exceeds 95% typically.

According to CEO Dr. Greene, "We made sure to partner with a lab that has a perfect safety record and only cultures cells between three and five generations. This means counts are high, and so is the potency of the cells!"

The treatment process starts with a free phone consultation with one of R3's licensed, experienced stem cell doctors. Once the treatment recommendation is made and the procedure is scheduled, the patient's designated concierge representative will assist with travel logistics. Transportation is included to and from the clinic from San Diego International Airport, which is only 20 minutes away.

Treatment starts at $2975 for 30 million live stem cells, and goes up $1000 for a total of 50 million. If a patient desires, a five day stay will include three treatments totaling 150 to 200 million stem cells. Or there is an option for four visits over a year as well, both starting at $8975 all inclusive.

To start the seamless process of obtaining treatment, visit for more information and call (888) 988-0515 to schedule the phone consultation.

Share article on social media or email:

See the original post:
R3 International Now Offering Stem Cell Therapy Program for Crohns Disease, IBD and Ulcerative Colitis - PR Web

Read More...

Nearly 2 years removed from serious back injury, Melstone cowboy J.R. Vezain continuing to progress – 406mtsports.com

Wednesday, July 1st, 2020

COLORADO SPRINGS, Colo. This fall will mark two years since PRCA bareback rider J.R. Vezain suffered a broken back after riding Frontier Rodeo Companys Brazos Bash, Sept. 22, 2018, at the Pasadena (Texas) Livestock Show & Rodeo.

The injury required surgery and left Vezain with mobility issues from the waist down.

In February, Vezain traveled to Panama City, Panama, for stem cell treatment, receiving intrinsic injections in his spinal column and intravenous injections in his arm for localized healing.

Everything went pretty smoothly, said Vezain, 28, in a PRCA press release. Ive noticed I have a little bit more control and consistent movement, but other than that its still just a slow process of healing.

Although the Melstone cowboy isnt walking yet, he continues to set goals to get there and said he is on the up.

I know God has a plan and his time is perfect, so I just keep trying to do something every day to get better and better myself, he said.

Vezain, a six-time qualifier for the National Finals Rodeo (2012-14, 2016-18), spent six months at a rehabilitation facility in Sandy, Utah, after the accident. Hes continued rehab exercises at his home gym, with his next goal being able to stand on his own.

My core is really strong, said Vezain, who previously resided in Cowley, Wyoming. Ive been working on balance, sitting on a balance ball and using discs. We have a walking machine where (with assistance) I walk and stretch. If I can stand, I can start to move my legs. I have enough control, like to crawl, and my hip flexor muscles are working. I have some leg movement, but Ive got to be able to stand first.

Vezain has also kept busy on the ranch, doing yard work, branding and gelding colts.

Ive also been busy doing leatherwork, I have a bunch of orders Im trying to catch up on, and just staying busy around the place, he said.

This year, Vezain began judging at bull riding events (not sanctioned by the PRCA).

As a rodeo cowboy, the last thing you ever think youre going to be is a rodeo judge, so that was something I had to get over, he said. But it keeps me connected and still involved in the sport. Its been fun being on the other side, really diving into rules and regulations, and knowing why a judge makes the calls they do. Its allowed me to get my mind off everything at the ranch and stay involved in rodeo.

Vezain said he keeps in touch periodically with his ProRodeo buddies. His brother-in-law Sage Newman of Melstone competes in saddle bronc riding.

The last rodeo I attended was in December (2019) to watch him compete, he said.

Vezain has done some motivational speaking at local high schools and churches. He also writes a monthly column for Rodeo News magazine.

Public speaking isnt really my forte, but every opportunity that has come up Ive been willing to share my story to hopefully provide some encouragement along the way, he said. I believe that every time Im asked to speak its for a reason and that somebody needs to hear the message.

Sharing his story also keeps Vezain motivated and grounded on achieving his goals.

My long-term goal would be to walk around and ride horses normally, he said. Ive always had dreams and aspirations to be able to train working cow horses. I want to be able to train horses again, play tackle football with my boy and work my ranch normally again.

On May 17, Vezains son, Ryatt, turned 1 year old.

Keeping up with him has also been a goal now that hes running amok.

Since the accident, Vezain said family and friends have helped in numerous ways, including assistance with remodeling his home and ranching needs.

Weve had a tremendous amount of help financially, physically, spiritually and emotionally from great people who are willing to reach out, he said. After the wreck, I put it all in Gods hands and said, Ill do my best to use the tools youve given me and the opportunity youve given me to spread your word. Ive always been willing to share my story and testimony to spark inspiration in others.

Read more:
Nearly 2 years removed from serious back injury, Melstone cowboy J.R. Vezain continuing to progress - 406mtsports.com

Read More...

Panama Stem Cell Clinic Reviews – Regenexx

Wednesday, February 12th, 2020

Yesterday I flew down to Grand Cayman to once again allow some of my patients access to advanced cultured stem cells. This morning I would also like to compare and contrast what we do here from whats done in Panama. Hence, this will be one of my first official Panama stem cell clinic reviews.

The cell therapies offered in the US are either autologous (from the patient) or allogeneic (from a donor). The only therapy in the US that has real stem cells and thats currently permitted by US law is bone marrow concentrate. All other donor cell offerings such as umbilical cord or amniotic tissue have no live and functional mesenchymal stem cell content (1-3).

Outside the US, the big difference is that the cells can be grown to larger numbers in a process called culture expansion. This means that the stem cells are grown over days to weeks in culture. They can also be saved for future use in cryopreservation.

There are three places close to the US that allow cells to be culture expanded and that have been around and stable for years. They are:

Today I will compare and contrast Regenexx Cayman with the Stem Cell Institute in one of my first Panama stem cell clinic reviews.

So why did I fly down to the Cayman Islands yesterday to treat my patients versus fly to Panama? As I have blogged before, the problem with Panama and Mexico and many Latin American clinics is that these countries dont usually permit US physicians to get a medical license. US patients have become very accustomed to the level of training we have in the states, but those US physicians cant be found in Latin America. Hence, one reason is that US physicians can and are licensed in Grand Cayman.

Another big difference is the technology offered. In Grand Cayman, the focus is on using the patients own stem cells from bone marrow and growing those in culture. In Panama, birth tissue cells are culture expanded. If we look at the amount of data published in human clinical trials on the use of cultured stem cells for orthopedic problems, theres simply much more safety and efficacy data published using bone marrow than birth tissues.

Finally, as I always discuss, precise injections of stem cells into specific areas require advanced training and tools. Meaning, the doctors in Cayman (including myself) are all US physicians who have additional training (certifications through IOF) on the use of fluoroscopy and ultrasound in how to place cells into the damaged musculoskeletal system. Having treated patients who were first treated in Panama, what you tend to get is blind and not image-guided advanced injections.

Heres a real patient stem cell order form the Cayman clinic this morning:

These are highly complex injections using both ultrasound and C-arm fluoroscopy. They cant be performed by an orthopedic surgeon or neurologist who doesnt have additional and advanced interventional training and there is no way to replicate these in Panama. In fact, from the patients that Ive treated who have also been treated there, the best that they could do would be blind injections in the knee, hand, and shoulder joints and to start an IV.

The upshot? Im here in Cayman instead of Panama because its the most advanced site close to the US to get orthopedic stem cell therapy. It allows US physicians to get licensed and only permits doctors who have advanced image-guided injection training to staff the clinic. Finally, there are the tools here that I need to do my work.

(1) Berger D, Lyons N, Steinmetz, N. In Vitro Evaluation of Injectable, Placental Tissue-Derived Products for Interventional Orthopedics. Interventional Orthopedics Foundation Annual Meeting. Denver, 2015.https://interventionalorthopedics.org/wp-content/uploads/2017/08/AmnioProducts-Poster.pdf

(2) Becktell L, Matuska A, Hon S, Delco M, Cole B, Fortier L. Proteomic analysis and cell viability of nine amnion-derived biologics. Orthopedic Research Society Annual Meeting, New Orleans, 2018.https://app.box.com/s/vcx7uw17gupg9ki06i57lno1tbjmzwaf

(3) Panero, A, Hirahara, A., Andersen, W, Rothenberg J, Fierro, F. Are Amniotic Fluid Products Stem Cell Therapies? A Study of Amniotic Fluid Preparations for Mesenchymal Stem Cells With Bone Marrow Comparison. The American Journal of Sports Medicine, 2019 47(5), 12301235. https://doi.org/10.1177/0363546519829034

Category: Uncategorized

Original post:
Panama Stem Cell Clinic Reviews - Regenexx

Read More...

Health care professionals offer insight to stem cell injection claims – WOWT

Wednesday, February 12th, 2020

OMAHA, Neb. (WOWT) -- Imagine the pain from nerve damage so severe you can hardly move, but hope for relief is being offered by a company pitching stem cell injections that dont come cheap

Ron Elliott may be willing to endure financial pain.

Elliott, a Neuropathy sufferer said, It could be $5,000 or so and whether insurance would cover any of it or not.

Thats the low-end cost of stem cell injections pitched by Vitality Nebraska in advertised seminars at metro area hotel conference rooms.

Vitality Nebraska presentation said, The reason this works so well is because of the source of the stem cells were using, very young vital capable cells from Dr. Riordans lab.

Neil Riordans resume lists a leading stem cell laboratory in Panama.

Many pain sufferers, mostly senior citizens attend the seminars and our request to record was denied, so Dr. James Billups wore a hidden camera.

The next day after the needle went in there it made me feel better, read the presentation.

Dr. James Billups said, They make broad claims on the ability to do this. Everything they presented was anecdotal and anecdotal is not science.

In a statement to Six on Your Side Vitality, Nebraska states, each patient is evaluated by a licensed practitioner to see if regenerative medicine is a viable option. We do not make any promises or guarantees.

Some of the worlds leading research in the use of stem cells for treatment is being done here at the University of Nebraska Medical Center. We brought the seminar video here to get a second and third opinion.

Dr. James Armtage an Oncologist said, You need to know for example with stem cells how are the cells being made, there are standards for the use of these things.

Dr. Lynell Klassen an Immunologist said, Its hard for me to understand how those cells would actually stay around long enough to repurpose itself and transform and reprogram in order to be a functioning cell.

Continued here:
Health care professionals offer insight to stem cell injection claims - WOWT

Read More...

U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa – Ottawa Citizen

Thursday, November 21st, 2019

Just a few months after Health Canada began cracking down on private clinics offering unapproved stem cell therapies, at least one U.S. clinic has moved in to fill the vacuum with direct marketing to Canadian consumers.

The clinic from Burlington, Vermont, even offers shuttle buses to transport people from Ottawa to the clinic four hours away for treatment it suggests will end joint pain, among other things. Lunch and dinner are free, but each injection costs $6,880. Two for $10,880.

The treatments, using umbilical cord-derived mesenchymal stem cells, are not approved in either Canada or the United States. Health Canada warns that Canadians who travel abroad for stem cell treatments may put themselves at risk.

While stem cells, which were discovered at the University of Toronto in 1961 by James Till and Ernest McCulloch, promise to revolutionize many treatments and could offer breakthroughs for diseases, almost all are still considered experimental and have yet to be proven safe or effective. Clinical trials on numerous potential stem cell therapies are under way, including in Ottawa.

While research progresses, private stem cell clinics have popped up around the world making promises for treatments not yet proven safe or effective.

A 2018 study by Leigh Turner of the University of Minnesota Center for Bioethics found 43 clinics offering stem cell treatments in Canada and 750 in the U.S. Earlier this year, Health Canada sent Canadian clinics, including some in Ottawa, cease-and-desist letters.

Clinics in Vermont, near the Canadian border, appear to have ramped up marketing to Canadians since then. One clinic has been holding back-to-back seminars. Another says it stopped marketing in Canada after receiving a warning from Health Canada.

There have been cases of harm as a result of treatments, including two women who had permanent damage to their sight after stem cells were injected into their eyes at a Florida clinic. Other patients have been infected with unsterilized equipment and others have developed tumours at the site of stem cell injections.

A common harm, critics say, is exploitation.

Dr. Michael Rudnicki is director of the regenerative medicine program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute, says of stem cell therapy claims: If it sounds too good to be true, it probably is too good to be true.jpg

Health officials say the clinics are misusing the promise of stem cell therapy to exploit vulnerable patients.

These patients are in pain and they are suffering and they are looking for help and they are being exploited, said Dr. Michael Rudnicki, director of the regenerative medicine program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute.

If it sounds too good to be true, it probably is too good to be true.

At a recent seminar at a west-end Ottawa hotel meeting room, Roseanna Ammendolea of the Vermont Center for Regenerative Medicine told a packed room that her clinic and others like it had successfully treated people for pain related to arthritis, neuropathy and other ailments that affected joints using mesenchymal stem cells from umbilical cords. The stem cells, she claimed, are both effective and safe, saying there had been no issues with cell rejection.

We will not give injections if we feel that this injection will not be beneficial to our patients. This is why we are so successful.

Participants, including some who walked with canes and others who talked about being in pain and having mobility issues, were shown videos of people described as Canadian clients who claimed the treatments worked. One man said it was probably the best money I have spent in my life as far as my health. Another said she would do it again in a heartbeat and was able to do things she hadnt been able to do earlier.

They were also shown a slide showing long wait times for hip and knee replacements in Ontario, We are not a priority, she said. Where does that leave us? Participants werent told exactly how the stem cells were supposed to work, but claimed they had successfully improved pain and mobility issues in clients.

What the seminar goers werent told is that, even in the U.S., the treatment is not covered by health insurance because it remains unproven.

The U.S. Federal Drug Administration has issued a warning to consumers not to use cell therapies that are unapproved or unproven.

Stem cells have been called everything from cure-alls to miracle treatments. But dont believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware of potentially dangerous procedures and confirm whats really being offered before you consider anytreatment, the FDA said in a statement.

The only stem-cell-based products that are FDA-approved for use in the United States are blood-forming stem cells derived from cord blood for limited use in patients with disorders affecting the body system that is involved in the production of blood. Bone marrow is also used for these treatments, but is generally not regulated by the FDA for that use.

Health Canada has granted market authorization for a stem cell therapy to treat graft-versus-host disease and two cell-based gene therapies to treat certain cancers. Most cell therapies are still experimental.

I totally understand the skepticism of it, Doug Argento, who works at the Vermont Center for Regenerative Medicine, said in a telephone interview, but the fact is that things that are approved now and medically paid for were seen as renegade 20 or 30 years ago.

The treatment employs technology developed by Neil Riordan, founder, chairman and chief science officer of the Stem Cell Institute in Panama, using human umbilical cord tissue-derived mesenchymal stem cells. There are 41 such clinics across the U.S. Riordan also played a role in the development of a nutritional product called Stem-Kine, which producers claim without scientific backing increases the number of stem cells circulating in a persons body.

The stem cells injected in the clinic, Argento said, are from umbilical cord tissue as a result of caesarean births to reduce risk of infection.

Rudnicki, of The Ottawa Hospital Research Institute, says there is no evidence that these sorts of cells are regenerative at all. It would not pass muster in Canada.

The public has to understand that there are people out to remove them from their money.

Rudnicki says he regularly receives inquiries from people desperate to get stem cell treatments. He says he tries to connect them with clinical trials that they might be able to participate in.

Rudnicki noted there were multiple clinical trials in Canada, including treatments of autoimmune diseases, trials involving treatment for Type 1 diabetes and others.

But the use of these inappropriate cell types for treating arthritis and joints and so on is certainly not approved by Health Canada and would not be allowed in Canada under the regulations.

There is some evidence that injections of some stem cell products might have a temporary positive impact on inflammation, he said, but it will not be regenerative and will not restore function to joints. They are being sold a bill of goods.

Leigh Turner of the University of Minnesota Center for Bioethics, meanwhile, says the explosion in clinics offering unproven stem cell therapies in the U.S. is a marketplace that traffics in misrepresentation. It is easy to see how people are taken advantage of and scammed.

It is also difficult to find out about physical harms being done to patients.

There are no safety studies. We dont have good data. But we do know there have been some serious harms.

Stem cell therapies have the potential to become standard treatment in some areas, but they are not there yet, Turner said.

Businesses are tapping into genuine human suffering, desperation and also hope.

Turner also noted there was an excellent chance that the vials of liquid being injected into patients did not actually contain stem cells.

Dr. Jonathan Fenton of another stem cell clinic in Burlington, the Vermont Regenerative Medicine, said he had complained about the new clinic, the Vermont Center for Regenerative Medicine, which has a similar name and employs hard-sell tactics, he said.

His clinic takes bone marrow from patients hips and injects it. The procedure is done the same day. He says he regularly sees Canadian patients for bone marrow aspiration therapy and platelet-rich plasma treatments, using their own blood. The treatments, he says, speed healing and are allowed in the U.S. The use of bone marrow aspiration is neither proven nor allowed in Canada.

Fenton, who is secretary-treasurer of the American Academy of Orthopedic Medicine, acknowledged many people offering stem cell treatments are not doing it to the highest ethical standards.

He has filed complaints with state officials over clinics selling unsafe or fraudulent treatments. I have asked the state and federal judiciary to close down this clinic for committing fraud.

He said his platelet and bone marrow treatments were covered by a major Vermont health insurer because they saw the cost of benefits were going down and patients were requiring fewer surgeries.

He said he was told by Health Canada that he could not market in Canada. Representatives of the Vermont Center for Regenerative Medicine, meanwhile, said they had discussions with Health Canada about what they could and could not say when marketing in Canada before holding seminars in Ottawa and Halifax.

We have looked at the information provided and have not identified any immediate non-compliance with advertising regulations pertaining to Canadian health products, a Health Canada spokesperson said, adding that the agency was continuing to assess.

Back at a west-end Ottawa hotel, some participants in the seminar, including a retired pharmacist, said they were considering getting the treatments. But its expensive.

Another participant said he was skeptical. They seemed very sketchy when I went online.

epayne@postmedia.com

ALSO IN THE NEWS

Hoffman and Kaushic: Were losing the fight against superbugs

Super-agers, who live to at least 110, boast stronger immune systems, helping them fight off diseases

Spinal-cord stimulator really promising: Survivor moves legs for first time since Humboldt bus crash

Excerpt from:
U.S. stem cell clinic offering unapproved therapies brings direct-to-consumer marketing to Ottawa - Ottawa Citizen

Read More...

Dr. Neil Riordan, Cell Therapy Expert – RMI Clinic | Stem …

Saturday, October 5th, 2019

Neil Riordan, PA, PhD is one of the early pioneers and experts in applied stem cell research. Dr. Riordan founded publicly traded company Medistem Laboratories (later Medistem Inc.) which was acquired by Intrexon in 2013.

He is the founder and chairman of Medistem Panama, Inc., a leading stem cell laboratory and research facility located in the Technology Park of the prestigious City of Knowledge in Panama City, Panama. Medistem Panama (est. 2007) is at the forefront of research on the effects of adult stem cells on the course of several chronic diseases and conditions. The stem cell laboratory at Medistem Panama is fully licensed by the Ministry of Health of Panama.

Human umbilical cord tissue-derived mesenchymal stem cells (hUCT-MSCs) that were isolated and grown at Medistem Panama to create master cell banks are currently being used in the United States. These cells serve as the starting material for cellular products used in MSC clinical trials for two Duchennes muscular dystrophy patients under US FDAs designation of Investigational New Drug (IND) for single patient compassionate use. (IND 16026 DMD Single Patient) These trials are the first in the United States to use hUCT-MSCs. Translational Biosciences, a fully-owned subsidiary of Medistem Panama is currently conducting phase I/II clinical trials for multiple sclerosis, autism and rheumatoid arthritis.

Dr. Riordan is founder, chairman and chief science officer of the Stem Cell Institute in Panama, which specializes in the treatment of human diseases and conditions with adult stem cells, primarily human umbilical cord tissue-derived mesenchymal stem cells. Established in 2007, Stem Cell Institute is one of the oldest, most well-known and well-respected stem cell therapy clinics in the world.

He is co-founder and chief science officer of the Riordan Medical Institute (RMI). Located in the Dallas-Fort Worth area city of Southlake, Texas, RMI specializes in the treatment of orthopedic conditions with autologous bone marrow-derived stem cells combined with amniotic tissue products developed by Dr. Riordan.

He is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals. Dr. Riordans team developed the product Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.

Dr. Riordan has published more than 70 scientific articles in international peer-reviewed journals. In the stem cell arena, his colleagues and he have published more than 20 articles on multiple sclerosis, spinal cord injury, heart failure, rheumatoid arthritis, Duchenne muscular dystrophy, autism, and Charcot-Marie-Tooth syndrome. In 2007, Dr. Riordans research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery, his team was honored with the Medical Article of the Year Award from Biomed Central. Other notable journals in which Dr. Riordan has published articles include the British Journal of Cancer, Cellular Immunology, Journal of Immunotherapy, and Translational Medicine.

In addition to his scientific journal publications, Dr. Riordan has authored two books about mesenchymal stem cell therapy: Stem Cell Therapy: A Rising Tide: How Stem Cells Are Disrupting Medicine and Transforming Lives and MSC (Mesenchymal Stem Cells): Clinical Evidence Leading Medicines Next Frontier. Dr. Riordan has also written two scientific book chapters on the use of non-controversial stem cells from placenta and umbilical cord.

Dr. Riordan is an established inventor. He is the inventor or co-inventor on more than 25 patent families, including 11 issued patents. His team collaborates with a number of universities and institutions, including National Institutes of Health, Indiana University, University of California, San Diego, University of Utah, University of Western Ontario, and University of Nebraska.

He has made a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father, Dr. Hugh Riordan, on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin Cs preferential toxicity to cancer cells notably led to a 1997 patent for the treatment of cancer with vitamin C. In 2010, Dr. Riordan was granted an additional patent for a new cellular vaccine for cancer patients.

Neil Riordan, PA, PhD earned his Bachelor of Science at Wichita State University and graduated summa cum laude. He received his Masters degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.

Link:
Dr. Neil Riordan, Cell Therapy Expert - RMI Clinic | Stem ...

Read More...

Mesenchymal stem cells, Umbilical Cord Tissue, Umbilical …

Friday, October 4th, 2019

Regenerative medicine may be the best hope for patients with a chronic disability or disease. Stem cells are being used to treat neurological, cardiovascular, autoimmune and orthopedic conditions as well as spinal cord injuries, severe wounds, erectile dysfunction and the list goes on.

Note: Despite all advances in stem cells research and the application of these therapies in many countries all over the world, stem cells therapies are not legally approved yet in San Diego, Los Angeles, Chicago, Dallas, New York, Jacksonville, Seattle, Houston, San Francisco, Salt Lake City, Miami, Beverly Hills and other US cities. However, stem cell treatments are legal in Costa Rica.

By regenerating tissue and organs, andreducing inflammation, human umbilical cord tissue mesenchymal stem cells (HUCT-MSCs)have demonstrated they have the ability to improve conditions that currentlyhave no, or few, treatment options.

Mesenchymal stem cells repair damagedtissue and organs, repair function, modulate the immune system and reduceinflammation. The most powerful and abundant source of mesenchymal stem cellsis found in gelatin of Whartons jelly in the the tissue of umbilical cords.

In September of 2018, researchers publishedthe results of their evaluation of more than 30 studies evaluating the regenerativebenefits of Whartons jelly, stem cells derived from the umbilical cord bloodand tissue and other products derived from the umbilical cord. https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-0992-0

Previously umbilical cord tissue wasconsidered medical waste and discarded, however, today experts in the field ofregenerative medicine, are preserving and using umbilical cord tissue to treatinjuries and chronic, degenerative conditions.

Whartons jelly is the gelatinous substancein the umbilical cord that protects and insulates the blood vessels. The jellyis made up of hyaluronic acid, chondroitin sulfate, collagen, fibrin, fibroblasts,macrophages and expresses stem cells including mesenchymal stem cells andtelomerase.

The review of available data, published in StemCell Research & Therapy, evaluated the benefits of products obtainedfrom Whartons jelly and discussed their potential clinical applications.

Whartons jelly can be used in several waysincluding: 1. The matrix surrounding the cells is made up of hyaluronic acid,collagen and fibrin that can be used to treat burns and wounds. The jelly isapplied to the damaged area to accelerate tissue restoration and 2. Adultmesenchymal stem cells can be isolated, cultured and expanded to treat diseasessuch as Alzheimers, Parkinsons, MS, Autism, spinal cord injury, rheumatoidarthritis, diabetes, traumatic brain injury.

The results of the data analysis showed theproperties of mesenchymal stem cells derived from Whartons jelly exceed thoseof stem cells derived from bone marrow and adipose tissue. HUCT-MSCs have beenshown to reduce inflammation, modulate the immune system, and repair damagedtissue.

HUCT-MSCs proliferate and differentiatemore efficiently and effectively than cells found in bone marrow and adiposetissue, and umbilical cord tissue is a more abundant source of mesenchymal stemcells than the blood of the umbilical cord.

Mesenchymal stem cells from the umbilical cord haveimmunosuppressors and immunomodulatory properties that allow their use in anyindividual without rejection. The cells do not express HLA-DR the antigenresponsible for rejection.

Researchers are conducting clinical trialsto evaluate the efficacy of stem cells derived from umbilical cord blood, andumbilical cord tissue. Some of the research includes:

Stem cells from umbilical cord tissue:

Stem cells from umbilical cord blood:

At the StemCells Transplant Institute in Costa Rica we recommend umbilical cord stemcells for the treatment of Alzheimers disease, Parkinsons disease, lupus,rheumatoid arthritis, multiple sclerosis, myocardial infarction, stroke,diabetes (type I and type II), spinal cord injury, neuropathy, COPD, and ALS.

Atthe Stem Cells Transplant Institute, we tailor each stem cell treatment,based on the patients individual needs and goals.

Humanumbilical cord mesenchymal stem cells and autologous mesenchymal stem cellshave been proven in clinical trials to be safe and effective.

Themission of the Stem Cells Transplant Institute in Costa Rica, is toprovide the highest level of care, using the most advanced technologies, toevery patient that wants to experience the life changing benefits of stem celltherapy.

Contactus today to learn more about the power of stem cell therapy.

Originally posted here:
Mesenchymal stem cells, Umbilical Cord Tissue, Umbilical ...

Read More...

STEM Summer Programs | TeenLife

Friday, October 4th, 2019

Careers involving STEM (Science, Technology, Engineering, and Mathematics) currently have the most job openings and offer the best entry-level salaries for college gradsestimated to be 30% more than average. We have researched and curated the largest online collection of STEM summer programs for students in grades 7-12, many of them precollege summer programs that take place on college campuses. Attending one of these programs is a great way for middle and high school students to experience college and learn more about potential STEM career paths. We also list hundreds of colleges that seek students interested in majoring in science, technology, computer science, engineering, math, and design.

Teen summer STEM programs allow high schoolers to develop their understanding in core subject areas that will matter to them now and in the future. Because Summer STEM for Teens is created not only to educate but also to be fun, teens who are only marginally interested in STEM subjects will find their curiosity sparked.

Science summer programs for teens offer hands-on experience that increases the ability to grasp critical scientific concepts. Great teen summer science programs focus on the scientific process and how to formulate and test hypotheses, and attendees enjoy improving their scientific knowledge.

Math summer programs for teens increase a students math skills through repetition and unique teaching techniques. Teen summer math programs emphasize one of the most important skills a student can have, while technology summer programs for teens help teens boost their proficiency with technology.

To see more of our listings, please join TeenLife

The rest is here:
STEM Summer Programs | TeenLife

Read More...

Stem Cell Therapy Cost? – Regenexx

Wednesday, October 2nd, 2019

There is no shortage of clinics out there offering stem cell therapy. How much does stem cell therapy cost? How much is too much? Are you getting what you pay for? Lets dig in.

Our focus here on stem cell therapy cost is for orthopedic procedures as thats our area of expertise and something where we can benchmark and compare apples to apples. However, before we can get into that, we must first discuss different types of treatment, which can be broken down into a couple of categories. Stem cell therapy cost generally depends on:

Youll see dollar signs below by each item in each category which Ill explain how to use later.

Whats being injected is critical to determining stem cell therapy cost. However, who is injecting it and where the procedure is performed and other details will modify these costs. We can break this part down into:

Numbers 1 and 2 here are procedures where all of the injections are performed on the same day, while number 3 takes a few weeks to grow cells. The advertised cost of birth tissue procedures and same-day bone marrow or fat procedures are similar, usually in the 4-8K USD range. However, this is where we find our biggest opportunity for patient rip-offs. Let me explain.

The biggest problem that we encounter in these same-day stem cell procedures is when the product has no live cells, let alone stem cells. Multiple studies now by university and private scientists demonstrate that the amniotic fluid and umbilical cord products being hawked at seminars all over the US are all non-viable tissue. So, right upfront, youre actually getting massively overcharged if a clinic claims that this is a stem cell procedure. In fact, these birth tissue procedures are more similar to platelet-rich plasma injections as both contain growth factors that can help healing, but neither contain stem cells. PRP procedures run in 1-2K range for a single joint, so thats the appropriate price range for birth tissue procedures. To find out more about the issue with birth tissues being advertised as stem cells, see my video below:

Culture-expanded cells are grown to bigger numbers over 1-3 weeks and then injected. These procedures can not be performed legally in the US, so they are performed in other countries like the Cayman Islands, Panama, parts of Europe, or China as examples. They generally run 15-30K.

Stem cell therapy cost should be tied to who performs these procedures. Which medical providers commonly inject the cells?

We regrettably dont see a big correlation between stem cell therapy cost and the level of training of the provider performing the procedure. For example, a nurse practitioner (NP) or physicians assistant (PA) has about half of the training of the average physician specialist, but the cost of a stem cell procedure performed by a nurse is often similar to a specialist physician. Obviously, a medical provider with far less training should cost less than one with twice the training.

Stem cell therapy cost is often tied to the location where the procedure is performed. For example:

One of the most interesting things out there in the world of stem cell procedures is that we see procedures being performed outside of medical clinics and hospitals, often in alternative medicine clinics. The issue is that the level of sterility, regulation, safety equipment, and technology is higher in a medical setting, but often alternative health clinics run by chiropractors, naturopaths, and acupuncturists charge just as much or more than actual medical clinics who have better technology and more highly trained staff. Hence, a procedure in a place thats barely capable of supporting you as a patient if something goes wrong should cost much less than a place designed to help you with the latest technology and most highly trained staff.

Stem cell therapy cost should also be tied to how the procedure is performed and commonly there a few treatment delivery types out there:

Starting an IV doesnt take much expertise. In addition, if you get stem cells intravenous, 97% will end up in your lungs and few will end up where you have pain, Hence, you need to inject them locally. One way to do that would be to inject them blind, without imaging guidance, which also takes little expertise. However, there is no way to tell if the cells got to where they were supposed to be placed. Finally, you can use imaging guidance to ensure that the cells will get to the right spot. Thats either ultrasound or fluoroscopy (real-time x-ray) or both. As a rule, you should pay much less for an IV or blind injection and more for an image-guided injection.

Stem cell therapy cost is often directly tied to the number of spots that get injected. For example:

Most clinics that inject joints to treat arthritis will inject simply into the joint, which should cost less as thats less work. Some clinics will also inject multiple structures within the joint or around it, adding time and expertise to the procedure. Injecting multiple joints would be a similar increase in work. Finally, some clinics will also inject multiple areas in and around multiple joints, which would be the most expensive.

To figure out the stem cell therapy cost take the price range above and apply the dollar sign modifiers. So single dollar signs should push you toward the low end of the price range and double or triple towards the higher end. Now lets take some concrete examples.

Example 1: A common stem cell procedure performed in a local chiropractors office.

As discussed above, the right price for birth tissues is about what you would pay for PRP, so thats 1-2K. All of these single dollars signs would push you toward a cost thats lower than the average stem cell therapy price. Hence, this is about a 1-2K procedure.

Now lets go to the other end of that spectrum: A bone marrow concentrate procedure delivered by a physician specialist in a medical office:

Same day bone marrow stem cell procedures run in the 4-8K range. All of these two dollars signs would push you toward the higher end of that range.

Obviously, we have dramatic differences in what I priced out above. The chiro clinic with a nurse injecting birth tissues blindly in a clinic not designed for this type of work is a lower quality affair. The opposite is true with my second example. So like anything else in life, you get what you pay for.

To learn more about how to choose the right stem cell clinic based on quality, read my mini-book on the topic (click on the book cover to download the PDF):

The upshot? Figuring out stem cell therapy cost is not that hard, you just need to know what it is youre buying. Just like that fake Gucci purse that looks good but falls apart in a few months, or that real one that lasts a lifetime, how much you spend is usually associated with the quality of what you buy. However, use the dollar signs to see if the stem cell procedure youre buying is over or underpriced!

Visit link:
Stem Cell Therapy Cost? - Regenexx

Read More...

Stem Cell Therapy for Autism at the Panama Stem Cell Institute

Saturday, September 14th, 2019

May 2019

Parents Guide to Cord Blood Foundation interview with Dr. Neil Riordan

The founder of Parents Guide to Cord Blood Foundation, Dr. Verter, had the opportunity to interview Dr. Riordan, the founder of the Panama Stem Cell Institute, during the annual meeting of the Perinatal Stem Cell Society in March 2019. This coverage is important for parents because it provides a concise summary of the Panama protocol for autism treatment. For cord blood bankers, this illustrates some factors that can contribute to a successful stem cell clinic.

This interview does not constitute an endorsement of the Panama Stem Cell Institute.

Many parents today are seeking stem cell therapy for a child with autism at the Stem Cell Institute located in downtown Panama City. The Panama Stem Cell Institute was founded by Neil Riordan PA PhD. Dr. Riordan is also a founder of the Riordan Medical Institute in Texas, and is involved with several companies in the field of regenerative medicine.

The popularity of the Stem Cell Institute in Panama arises from several factors. The clinic provides therapies using specially screened and processed mesenchymal stem cells (MSC) sourced from umbilical cord (UC) tissue that has been donated after normal, healthy births. These UC-MSC can safely be given to patients without any matching to the donor. Since the Stem Cell Institute does not use cord blood, parents do not have to worry about whether they banked cord blood for their children, whether the cord blood they banked is viable, or how to ship the cord blood to Panama. Once accepted and scheduled for treatment, the family travels to Panama and the clinic provides the stem cells. Both the clinic and accompanying laboratory in Panama are fully licensed by the national medical authorities and adhere to international standards. Parents can feel confident that the therapy is legal, the stem cells are sourced and prepared in an affiliated laboratory, and the clinic is highly experienced. The waiting list at Panama is only a few months, which is important to parents who want to try stem cell therapy while their childs brain is still developing.

The Stem Cell Institute provides families with a comprehensive five-day package that includes expedited customs clearance and a hotel room at the Hilton, which is connected to the clinics office tower. The price ranges from around $13,000 to $18,000 depending on the childs weight. For children with autism, the first day of the treatment, a Monday, is dedicated to intake testing. On days Tuesday through Friday, the child receives daily intravenous infusions of stem cells suspended in sterile solution. The four infusions deliver a total dosage of 40 to 80 million UC-MSC, depending on the childs weight.

The safety profile of the Panama Stem Cell Institute is well established. Since the clinic opened in 2006, they have performed over 10,000 procedures, and currently they are treating up to 200 patients per month. A patient registry safety review performed over nine months in 2018 found 497 adverse events (AE) out of 3058 treatments administered, which is a rate of 16.2%. The vast majority of AE (15.8%) were mild symptoms, consisting of fatigue and headache. The worst AE, consisting of nausea and vomiting, were only reported by 0.13% of patients.

A clinical trial for autism, registered by the clinic in 2014, has been completed with 20 participants. A paper was submitted to a peer-reviewed medical journal and is currently under review. In the final paper, outcomes were measured using Autism Treatment Evaluation Checklist (ATEC) scores, Childhood Autism Rating Scale (CARS) scores, macrophage-derived chemokine (MDC) levels and activation-regulated chemokine (TARC) levels recorded at baseline and again at 13 weeks, 25 weeks, 37 weeks, 49 weeks, and 89 weeks post-therapy.

At the Perinatal Stem Cell Society meeting, Dr. Riordan presented data on 47 autism patients selected from the clinic patient registry (movie link at bottom of the page). Among these patients, 87% were boys, the median patient age was 7 years old, and the daily dose averaged 15.75 million UC-MSC. For these patients, ATEC scores were compared at baseline and six months. The scores showed improvements in the categories of speech, sociability, awareness, and behavior; and all of the improvements had high statistical significance.

Parents contemplating autism therapy at Panama are encouraged to rule out other conditions that can cause autism symptoms, such as genetic disorders and heavy metal poisoning. Normal blood test readings for heavy metals are mandatory before enrolling for therapy.

Parents wishing to learn more about autism therapy at the Stem Cell Institute in Panama can visit the autism treatment page on the clinic website. There is an unaffiliated Facebook group, Stem Cell Therapy for Autism, which is run by parents for parents as a forum to share experiences with stem cell therapy.

Parents Guide to Cord Blood Foundation explains the rationale behind autism therapy with either cord blood MNC or cord tissue MSC in our companion article, Everything parents should know about stem cell therapy for Autism.

View original post here:
Stem Cell Therapy for Autism at the Panama Stem Cell Institute

Read More...

Cost of Stem Cell Transplant – Beike Biotechnology

Saturday, September 14th, 2019

Stem cell treatment is regularly in the news around the world. Mostly the topics revolve around safety, efficacy, or ethics. health insurance, Lately however, the price of these treatments has also been highlighted. Our stem cell provider,Beike Biotechnology, recently released their new stem cell therapy protocol in hopes of cutting treatment cost.

Other treatment providers in the news have been advertising prices from 50,000 USD to 200,000 USD.

Despite the thousands of positive research papers and clinical trials showing the effectiveness of stem cells the treatment is not readily available in most countries, especially not at a reasonable price. In the USA for example, it is possible to receive a stem cell treatment for Multiple Sclerosis. The bad news is that it will cost around $125,000 per patient, not including any drugs or supportive therapies. Also, this type of cell therapy (hematopoietic stem cell transplant) is not effective in progressive MS.

Similarly, a New Zealand man with Multiple Sclerosis is traveling to Singapore for hematopoietic stem cell treatment. The cost of this treatment is $200,000. Also, according to Associate Professor Bronwen Connor from Auckland University, in regards to hematopoietic stem cell transplants international trials showed the symptoms could recur over time and there were also some deaths associated with the treatment that were higher than would be acceptable for clinical practice.

Our treatment, specifically the new protocol from Beike Biotechnology was designed with progressive conditions in mind and utilizes umbilical cord blood and mesenchymal adult stem cells, which have had no history of adverse side-effects in thousands of clinical trials and treatments.

Another news story highlighted a Spinal Cord Injury (SCI) patient who paid $50,000 for a treatment in Panama. At this time this patient has not seen any significant improvements.

Our medical team recommends extensive physical and occupational therapy in combination with stem cell treatment for Spinal Cord Injury SCI which is offered at our partner treatment center Better Being Hospital. Our stem cell treatment protocol includes 6 injections of umbilical cord mesenchymal stem cells over 25 days with intensive rehabilitation is almost half Panamasstem cell institute cost which is $31,000.

Also, late last year spinal epidural stimulation, in combination with stem cell therapy, was found to be a very effective treatment option for SCI, allowing patients to voluntarily move their previously paralyzed limbs. In total, our comprehensive stem cell + epidural stimulation treatment is less than $80,000 for a 45 day intensive rehabilitation.

Our comprehensive treatment using umbilical cord stem cellsstarts at $12,000. For detailed information regarding our treatment packages

Excerpt from:
Cost of Stem Cell Transplant - Beike Biotechnology

Read More...

What Stem Cell Clinics Do You Trust? | BioInformant

Saturday, May 4th, 2019

Be in the know about leading stem cell centers you can trust in this article.

In this article:

Stem cell clinics have received a great deal of negativepress,with prominent media outlets announcing that the Food and Drug Administration (FDA) had mailed Warning Letters to stem cell centers across the United States.According to a paper published in the journalCell Stem Cell in June 2016,at least 351 businesses offer unproven stem cell interventions fromclinics spread across the U.S.

Shortly after publication, the MIT Technology Reviewand Washington Postpicked up the story, spreading the fear far and wide.Journalists then got enthralled with the story, calling it the Wild West of stem cells.

But, is this the whole story?

What this hype does not cover isthe promising medical potentialof stem celltherapies, nor had it properly credited the legitimate stem cell clinics that comply with FDA regulations to offer effective medical treatments to populations of patients who otherwise have limited options.

Today, the majority of medical clinics that offer stem cell treatments administer mesenchymal stem cells (MSCs), which they source from human fat (adipose tissue) orbone marrow.

Mesenchymal stem cells are a type of multipotent stem cell that is administered for a range of medical applications, including orthopedic repair, pain management, arthritis, and asthma.

When properly administered, multipotent self-derived stem cells (such as MSCs) can be safe for patient use.

It is important that the cells be multipotent (limited in their differentiation capacity), rather than totipotent (can become any cell) or pluripotent (can become most cells). There is also an additional level of safety that comes from having stem cells be self-derived, which doctors and scientists call autologous.

Stem cell differentiation capacity is explained below:

While it is true that many stem cell centers are not properly regulated, the therapeutic promise of stem cells is also clear.

Today, nearly 30,000 scientific publicationshighlight research and therapeutic advanceswith mesenchymal stem cells (MSCs), and approximately850+ clinical trials are investigating therapeutic uses of MSCs. Additionally, 300,000+ scientific publications about stem cells have been released.

This momentum is not surprising, because We are not made of drugs, we are made of cells.

However, the biggest issue with the hype surrounding stem cell centers is that it does not give proper credit to the companies that cooperate with regulatory bodiesto ensure a safe and efficacious patient experience. Many of these companies also collaborate withoffshore regulatory bodies to offer stem cell procedures approved by local regulatory agencies.

The FDAsCenter for Biologics Evaluation and Research (CBER)regulates human cell and tissue-based products in the U.S., known as HCT/Ps. The FDA has two different paths for cell therapies based on relative risk.

These pathways are commonly called 361 and 351 products.

The 361 products that meet all the criteria in 21 CFR 1271.10(a)are regulated as HCT/Ps and are not required to be licensed or approved by the FDA. These products are called 361 products because they are regulated under Section 361 of the Public Health Service (PHS) Act.

In contrast, if a cell therapy product doesnot meet all the criteria outlined in 21 CFR 1271.10(a), then it is regulated as a drug, device, or a biological product under the Federal Food, Drug, and Cosmetic Act (FDCA) and Section 351 of the PHS Act.[1]

These 351 products requireclinical trials to demonstrate safety and efficacy in a process that is nearly identical to that what is required for pharmaceutical products to enter the marketplace.

Stem cell centers must ensure that their treatments meet the FDAs criteria to be classified as 351 products.

Below, we cover five leading stem cell centers. Each one has treated large populations of patients with adult stem cells. At least one (Regenexx) is maintaining a Patient Registry to document long-term patient outcomes.

We are not advising patients to seek treatments from these companies.We are identifying them to allow readers to seek out more information.

Founded by Dr. Neil Riordan, a globally recognized stem cell expert and visionary, the Stem Cell Institute in Panama is among the worlds leaders in stem cell research and therapy. Their treatments focus on well-targeted combinations of allogeneic umbilical cord stem cells, as well as autologous bone marrow stem cells.

The stem cells clinic uses stem cell therapies to treat various ailments, including the following:

One of their most recent studies exhibited the clinical feasibility of stem cell transplant process as a safe and effective treatment approach for patients with multiple sclerosis (MS).

Published in the Journal of Translational Medicine, the study showed that umbilical cord stem cells can slow down MS disease progression and decrease the frequency of flare-ups.

However, these stem cells did not exhibit the ability to repair damaged nerve cells or myelin sheaths.

After the completion of this clinical study, there was an improvement in MS patient disability. The 1-month mark of the study documented improvements in mobility, hand, bladder, bowel, and sexual functions. Importantly, the study demonstrated that a sustained one-year umbilical cord stem cell therapy has more durable benefits than current MS drug therapies.

Headquartered in Denver, CO, Regenexx offers self-derived (autologous transplant) same-day stem cell treatments to patients with orthopedic injuries and conditions. Regenexx clinicsincorporate a variety of regenerative approaches, drawing patients from all over the U.S. who are seeking innovative, non-surgical treatments.

TheRegenexx technologyinvolvesa procedure in whicha small bone marrow sample is extracted through a needle and blood is drawn from a vein in the arm. These samples are then processed in a laboratory and the cells they contain are injected into the area needing repair, with the goal of delivering large numbers of stem cells to the site of injury.

Regenexx is also a licensedoffshore clinic in the Cayman Islands where patients can undergo treatments that utilize laboratory-expanded (ex vivo) stem cell populations. This approach allows for a much larger number of stem cells to be administered to the patient than is supported by U.S. law, which currently prohibits laboratory procedures that the FDA considers to exceed minimal manipulation.

Dr. Christopher Centenois the Founder and CEO of Regenexx. He is a global authority in the culture expansion and clinical use of adult stem cells to treat orthopedic injuries and thevisionary behind the Regenexx technology.

I am also a Regenexx patient.Click here to read my experience.

Founded in 2011,Okyanosis a stem cell therapy provider that specializes in treating patients with congestive heart failure (CHF) and other chronic degenerative conditions. Okyanos Cell Therapy uses internationally-approved technology to deliver a mixed population of fat (adipose) derived stem and regenerative cells (ADRCs) to patients with conditions such as the following:

Okyanos maintains both a North American Office in Clearwater, FL, and a purpose-built Cell Therapy Surgical Center inFreeport, GrandBahama. Okyanos stem cell treatments are performed in their state-of-the-art surgical centers under the care of board-certified doctors.

Okyanos is also fully licensed and regulated under the Bahamas Stem Cell Therapy and Research Actand adheres to U.S. surgical center standards. Click here to access our recent interview withMatthew Feshbach, Co-Founder and CEO of Okyanos.

The Global Institute of Stem Cell Therapy and Research (GIOSTAR) provides adult stem cells for autologous and allogeneic stem cell therapy to patients around the world, based on research byDr. Anand Srivastava. The stem cell clinic offers adult stem cells for rejuvenation treatment, muscular injuries, and degenerative diseases.

Each of GIOSTARs clinics is licensed for the application of stem cell therapy.Since 2000, its team of scientists and clinicians have been developing and utilizing stem cell-based clinical protocols for the purpose of stem cell treatment.

Although the company is headquartered in San Diego, California, GIOSTAR Mexico has provided stem cell therapy to patients from all over the world. Mexicos regulation of stem cell therapeutics differs from the regulations imposed by the U.S. FDA, making it a growing site for medical tourism.

Celltex specializes in cryopreserving mesenchymal stem cells (MSCs) for therapeutic use. Celltex acquires stem cells by collecting a small fat sample from a patient, from which MSCs are extracted,isolated, multiplied, and stored for future use (known as cell banking).

Patients can then use their stored stem cells for regenerative purposesthrough infusions or injections performed by a licensed physician.

Because the FDA considers an individuals stem cells a drug if they have been expanded in large quantities, Celltex has begun the process of undertaking clinical trials on stem cells as a treatment for a range of medical conditions, seeking approval from the FDA to allow physicians to utilize these cells.

Nonetheless, to meet the immediate needs of its clients, the company also has taken steps to meet the requirements of the FDA and COFEPRIS, a Mexican institution equivalent to FDA in MSCs import and export.

Celltex also works with Mexican hospitals that are established and certified that allowed the companys cell-banking clients to receive their stem cells for medical purposes.

Although these leading stem cell centers have built a good reputation in regenerative medicine, it is still important to probe these clinics before the proper procedure. These questions should cover what to expect from the treatment, safety and emergencies, cost, and the patients rights.

Treatment

Safety and Emergencies

Costs

Patients Rights

Understanding how these leading stem cell centers operate and what they do allows the patient to assess which of them is the right investment. While the information above is important to understand from a scientific and regulatory perspective, patient experiences are valuable too.

If you found this blog valuable, subscribe to BioInformants stem cell industry updates.

As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, we encourage you to join more than half a million loyal readers, including physicians, scientists, executives, and investors.

Have you had a stem cell transplant?What stem cell clinic did you use? What treatment did you get and for what condition? Share your answers in the comments below.

Footnotes [1] Aabb.org. (2017). Cellular Therapies. [online] Available at: http://www.aabb.org/advocacy/regulatorygovernment/ct/Pages/default.aspx [Accessed 1 Aug. 2017].

What Stem Cell Clinics Do You Trust?

Here is the original post:
What Stem Cell Clinics Do You Trust? | BioInformant

Read More...

Human Umbilical Cord Stem Cells for … – Medistem Panama

Wednesday, February 6th, 2019

Abstract

Osteoarthritis (OA) is a chronic degenerative condition of the articular cartilage, which is the most common cause of disability in patients over age 65. Treatment options are limited towards alleviating symptomology.

Mesenchymal stem cells (MSC) are effective at treating osteoarthritis (OA) in animal models and clinical trials [1-6]. Mechanisms of therapeutic activity appear to be associated with regenerative and anti-inflammatory factors produced by MSC [7, 8]. On the one hand, MSC produce soluble factors that are antioxidant [9], antifibrotic [10], and stimulate endogenous chondrogenic progenitors [11], on the other hand MSC directly can differentiate into cartilage tissue [12].

The proposed study will involve intra-articular injection of umbilical cord tissue mesenchymal stem cells (UC-MSC) into joints of 20 patients with grade 2-4 radiographic OA severity and intravenously in 20 patients with grade 2-4 radiographic OA severity. The primary endpoint will be safety and feasibility as assessed by lack of treatment associated adverse events. The secondary endpoint will be improvements in joint function as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Patients will be examined at baseline and 3 and 12 months after treatment.

This, study will provide support for double-blind placebo controlled investigations. The potential of using UC-MSC for this debilitating condition will open the door for future investigations in other inflammatory conditions if results demonstrate safety and feasibility of this approach.

Follow this link:
Human Umbilical Cord Stem Cells for ... - Medistem Panama

Read More...

The Cost Of Stem Cell Therapy And Why It’s So Expensive …

Monday, February 4th, 2019

How much is stem cell therapy? As stated by CBC Canada,the cost of stem cell therapy is $5,000 to $8,000per stem cell treatment for patients. According to a Twitter poll by BioInformant, the cost can be even higher. Our May 2018 poll found that stem cell treatments can cost as much as $25,000 or more. This article explores the key factors that impact the cost of stem cell therapy, including the type of stem cells used within the protocol, the number of treatments required, and the site of theclinic. It also provides pricing quotes from stem cell clinics within the U.S. and worldwide.

In this article:

Stem cell therapy is the use of living cells as therapeutics to treat disease or injury. Read on to learn about the cost requirements of these procedures.

CBC Canadas pricing involves Cell Surgical Network (CSN) following its protocol to remove fat tissue and process it before re-injecting [adipose-derived stem cells] either directly or intravenously into the same patient. Unfortunately, the U.S. FDA and Department of Justice (DOJ) sent this network of stem cell treatment providers a permanent injunction notice in May 2018. Therefore, patients should not seek treatments from the group at this time.Although Cell Surgical Network (CSN) is based in California, it has a network of approximately 100 U.S. treatment centers. They also have three Canadian clinics located in Vancouver, Sudbury,andKamloops.

The controversy such as the one above stirs up questions about the safety of stem cell procedures. Anyone considering stem cell therapy from any tissue or source will benefit from understanding the possible consequences of stem cell therapy and the factors driving costs.

For the patient, a stem cell transplant involves multiple steps, including:

There are also real costs for the doctors who provide stem cell treatments. They have overhead costs, including:

There is also time and expertise required toperform the procedure and offer post-operative care. In some cases, the physician must pay licensing fees to access stem cell sourcing, processing, or delivery technologies.

Stem cell treatment has gained more and more traction over the last decade. It has been helped along by considerable advances in research. In 2017, the number of scientific publications about stem cells surpassed 300,000. The number of stem cell clinical trials has also surpassed4,600 worldwide.

However, stem cell therapy is still expensive. Among the cheapest and easiest options is to harvest adipose-derived stem cells (ADSCs) those that exist in adult fat layers and re-deliver them to the patient. Unlike harvesting from bone marrow or teeth, providers can feasibly remove fat, separate stem cells, then re-inject them into a patient the same day. This approach is typically less expensive than those that require more invasive procedures for harvesting. Because of its practicality in terms of cost, it has become a common approach to stem cell treatment.

Relatively easy harvesting stilldoesnt translate to inexpensive cost, although some are certainly more affordable than others. For orthopedic conditions, the costof stem cell therapy is typically lower, averaging between $5,000 and $8,000. Examples of these types of medical conditions include:

Note that these prices are typically out-of-pocket costs paid by the patientbecause most insurance companies will not cover them. They are considered experimental and unapproved by the FDA. This means patients needing stem cell treatment will need to use their own savings.

Although fat is a frequently utilized source for stem cells, it is also possible for physicians to utilize stem cells from bone marrow. Regenexx provides this service in the U.S. and Cayman Islands. With theRegenexxstem cell injection procedure, a small bone marrow sample is extracted through a needle, and blood is drawn from a vein in the arm. These samples are processed in a laboratory, and the cells it contains are injected into an area of the body that needs repair. On June 19, 2018, ACAP Health, a leading provider in innovative, clinical-based solutions partnered with Regenexx to reduce high-cost musculoskeletal surgeries.ACAP Health is a national leader in employer healthcare expense reduction. It is one of the first healthcare groups to partner with a stem cell treatment group to support insurance coverage to patients.

A recent Twitter poll conducted by BioInformant reported that, on average, patients can expect to spend $25,000 or more on stem cell therapies. According to the poll,

Most likely, those paying lower stem cell treatment costs under $5,000 were pursuing treatment for orthopedic or musculoskeletal conditions. In contrast, those paying higher treatment costs were likely getting treated for systemic or more complex conditions, such as diabetes, multiple sclerosis (MS), neurodegenerative diseases (such as Alzheimers disease or dementia), psoriatic arthritis, as well as the treatment for autism.

In the U.S., treatment protocols vary depending on the clinic and the treating physician. A one-time treatment that utilizes blood drawn from a patient can cost as little as $1,500. However, protocols that utilize a bone marrow or adipose (fat) tissue extraction can run as much as $15,000 $30,000. This is because bone marrow extraction is an invasive procedure that requires a penetrating bone and adipose tissue extraction requires a medical professional trained in liposuction.

For treatments that require a systemic or whole-body approach, the cost tends to be in the higher range, often averaging from $20,000 to $30,000. Examples of the diseases or conditions requiring this type of stem cell treatment include:

These higher costs reflect the complexity of treating these patients and the fact that multiple treatments are often required.

Founded by Dr. Neil Riordan, a globally recognized stem cell expert, theStem Cell Institutein Panama is one of the worlds most trusted adult stem cell therapy centers. Over the past 12 years, the center has performed more than10,000 procedures, making it a widely recognized destination for stem cell treatments.

Working in collaboration with universities and physicians worldwide, its stem cell treatment protocols utilize combinations of allogeneic human umbilical cord blood stem cells and autologous bone marrow stem cells to treat a wide variety of conditions.

A reader of BioInformant was recently treated for psoriatic arthritis at the Stem Cell Institute in Panama in early 2018. The price of his stem cell treatment was $22,000. With travel and lodging included, the total expenses were approximately $30,000.

Because of its proximity to the U.S., Mexico is increasingly becoming a destination for medical tourism.Before choosing a stem cell treatment provider in Mexico, ensure the clinic is fully authorized by COFEPRIS, the Mexican equivalent to the FDA.

One patient who recently shared stem cell treatment quotes with BioInformant found that the treatment for glycogen storage disease, a metabolic disorder that often onsets in infancy and continues into adulthood, would cost $23,900 throughGIOSTAR Mexico.

In contrast, the patient was quoted$33,000 throughCelltex, a U.S.-based company that treats patients in Cancun, Mexico.Celltex follows FDA regulations concerning the export of cells to Mexico and is compliant with the standards and procedures of COFEPRIS. Celltex also has an alliance with a certified hospital in Mexico, which is approved to receive cells and administer them to patients by a licensed physician.

In contrast, the patient was quoted $10,000 from Stem Cell Therapy of Las Vegas and Med Spa, an American clinic. This price difference may reflect regulatory restrictions that prevent U.S. providers from expanding cells. It may also reflect the therapeutic approach used by the clinic, as well as the quality of their expertise.

In Mexico, where certain types of stem cell expansion are allowed that are restricted within the U.S., treatment protocols vary depending on the clinic and the treating physician. A one-time treatment that utilizes peripheral blood from a patient can cost as little as $1,000. In contrast, protocols that utilize more invasive sources of stem cells can run as much as $15,000 $35,000. Examples of invasive procedures includebone marrow and adipose tissue extraction. In some cases, hospitalization may be required, which raises costs. The location of a stem cell facility can factor heavily into thecost of the procedure.

Not every cost associated with treatment gets billed to the patient at the time of the procedure. Hidden costs such as reactions to the treatment, graft-versus-host disease, or disability derived from the treatment can all result in more money to the patient, to insurance, or to the government.

For example, in the case of someone with cancer, it frequently isnt viable to harvest the patients own stem cells because they may contain cancerous cells that can reintroduce tumors to the body. Instead, the patient would receive stem cells by transplant. Treatments that involve cells from another person are called allogeneic treatments. The danger here is that the body may see those cells as invaders and attack them via the immune system, a condition known as graft-versus-host disease (GvHD). The body (host) and the introduced stem cells (graft) then battle rather than coexist.

Transplanted cells often face the risk of being rejected by their host; this article discusses the effect of plasma exchange on acute graft vs. host diseasehttps://t.co/cA3nzFntew

Katie Bunde (@kbuns76) May 29, 2018

In addition to making the stem cell treatments less effective or ineffective, GvHD can be deadly. Roughly30 to 60 percent ofhematopoieticstem cell and bone marrow transplantationpatients sufferfrom it, and of those, 50 percent eventually die. The hospital costs associated with it are substantial.

Another hidden cost is the potential to disrupt a system that formerly functioned adequately. The best current example of this isthe case of Doris Tyler, who received bilateral stem cell injections in her eyes from Drs.RobertHalpernand JamieWalraven of Stem Cell Center of Georgia. According to her, while her vision was failing, it was still good enough to perform various tasks, and now it is not. That means the cost increases for her, as well as potential insurance or disability claims (though again, insurance is unlikely to cover the specific consequences of this action).

Because of tight regulations surrounding stem cell procedures performed in the United States, many stem cell treatment providers provide both on-shore (U.S.-based) and offshore (international) treatment options.Depending on where a treatment is received, patients may have to pay travel, lodging,and miscellaneous expenditures.

For example, Regenexx offers treatments at a wide range of U.S. facilities using non-expanded stem cells. However, it also offers a laboratory-expanded treatment option at a site in the Cayman Islands, which can administer higher cell doses to patients by expanding the cells in culture within a laboratory.

Similarly, Okyanos (pronounced Oh key AH nos) offers treatments to patients at its Florida location and provides more involved stem cell procedures at its offshore site inGrand Bahama. It was founded in 2011 and is a stem cell therapy provider specializing in treatments for congestive heart failure (CHF) and other chronic conditions. It is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards.

Similarly, Celltex is headquartered in Houston, Texas, but offers stem cell treatments in Cancun, Mexico. Celltex specializes in storing a patients mesenchymal stem cells (MSCs) for therapeutic use.

While no hard evidence yet points to stem cell clinics raising their rates as a result of lawsuits, that is a typical response in industries whose products or services the public perceives as a high risk.

An additional danger to stem cell treatment providers,points out Nature, is the reduction of bottom-line profits through former patients winning suits. If clinics have to pay out the money they earned and then some to individuals suing for damages, they may soon become faced with an unviable business model. That is a definite concern for those hoping to leverage these treatments now and in the future.

As with any other area of medicine, patient evaluations of stem cell providers and treatments run the gamut from extremely satisfied to desolately unhappy. Those like Doris Tyler who have lost their eyesight exist at the negative end of the spectrum. However, many others praise stem cell treatments for their power to heal diseases, boost immunity, fight cancer, and more.

For example, BioInformants Founder and President, Cade Hildreth, had a favorable experience with stem cell therapy. Cade had bone marrow-derived stem cells collected and then had them re-injected into the knee to treat a devastating orthopedic injury. Cade was able to reverse pain, swelling, and scarring to reclaim an elite athletic ability.

As of now, this much is clear. There exists enough interest in America and across the world that stem cell providers are continuing to offer a wide range of treatments. Stem cell treatments also offer the potential to reverse diseases that traditionally had to be chronically managed by drugs. Like most medical practices, stem cell treatments will require further testing to reveal merits and faults. Until then, the public will likely continue to pursue services when medical needs arise.

Although the cost of stem cell therapy is pricey, some patients choose to undergo the treatment because it is more economical than enduring the costs associated with chronic diseases.

Although most stem cell therapy providers do not provide FDA-approved procedures, the Food and Drug Administration (FDA) continues to encouragepatients to pursue approved therapies, even if there is a higher associated treatment cost.

Providers rarely post their prices for stem cell treatments in print or digital media because they want patients to understand the benefits of therapy before making a price decision. Additionally, the price of stem cell treatments varies by condition, the number of treatments required, and the complexity of the procedure, factors that can make it difficult for medical providers to provide cost estimates without a diagnostic visit for the patient. However, in many cases, it is not in the patients best interest to make treatment decisions based on the cost of stem cell therapy. The best way to know whether to pursue stem cell therapy is to explore patient outcomes by condition and compare the healing process to other surgical and non-surgical treatment options.

The cost of stem cell therapy is indeed expensive, especially because the procedures are rarely covered by health insurance. However, with the right knowledge and a clear understanding of the treatment process, the risk of undergoing stem cell therapy can be worth it, especially if it removes the requirement for a lifetime of prescription medication. Although stem cell therapy has associated risks, it has improved thousands of lives and will continue to play in a key role in the future of modern medicine.

Download this infographic for your reference:

Are you seeking a stem cell treatment? If so, we have partnered with GIOSTAR to help you acccess medical guidance and advice.

In alignment with what we believe at BioInformant, GIOSTARs goal is to offer cutting-edge, extensively researched stem cell therapy options designed to rejuvenate and improve a patients quality of life.

Click here to Schedule a Consultation or ask GIOSTAR a question.

If you found this blog valuable, subscribe to BioInformants stem cell industry updates.

As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, we encourage you to join more than half a million loyal readers, including physicians, scientists, executives, and investors.

Do you think the cost of stem cell therapy is too much? Share your thoughts in the comments section below.

Up Next: Japan to Supply Human Embryonic Stem Cells (hESC) for Clinical Research

Cost Of Stem Cell Therapy And Why Its So Expensive

Continue reading here:
The Cost Of Stem Cell Therapy And Why It's So Expensive ...

Read More...

Stem Cell Treatments and Therapies from Beike Biotechnology

Monday, February 4th, 2019

Acupuncture

Acupuncture is a technique in which practitioners stimulate specific points on the body - most often by inserting thin needles through the skin. It is one of the most effective practices used in traditional Chinese medicine. Acupuncture stimulates nerve fibers to transmit signals to the spinal cord and brain, activating the bodys central nervous system. The spinal cord and brain then release hormones responsible for making us feel less pain while improving overall health. Acupuncture may also: increase blood circulation and body temperature, affect white blood cell activity (responsible for our immune function), reduce cholesterol and triglyceride levels, and regulate blood sugar levels.

Aquatherapy

Aquatic Physical Therapy is the practice of physical therapy in a specifically designed water pool with a therapist. The unique properties of the aquatic environment enhance interventions for patients with neurological or musculoskeletal conditions. Aquatic therapy includes a wide range of techniques allowing patients to improve their balance, muscle strength and body mechanics. Aquatic therapy works to enhance the rehabilitation process and support effectiveness of stem cell treatment.

Epidural Stimulation

Hyperbaric Oxygen Therapy

Hyperbaric Oxygen Therapy (HBOT) is the medical use of oxygen at a level higher than atmospheric pressure. The equipment required consists of pressure chamber, which may be of rigid or flexible construction, and a means of delivering 100% oxygen into the respiratory system. Published research shows that HBOT increases the lifespan of stem cells after injection and provides an oxygen-rich atmosphere for the body to function at optimum levels.

Nerve Growth Factor (NGF)

Nerve growth factor (NGF) is a member of the neurotrophic factor (neurotrophin, NTFS) family, which can prevent the death of nerve cells and has many features of typical neurotransmitter molecules. NGF plays an important role in the development and growth of nerve cells. NGF is synthesized and secreted by tissues (corneal epithelial, endothelial, and corneal stromal cells), and it can be up-taken by sympathetic or sensory nerve endings and then transported to be stored in neuronal cell bodies where it can promote the growth and differentiation of nerve cells.NGF can exert neurotrophic effects on injured nerves and promote neurogenesis (the process of generating neurons from stem cells) that is closely related to the development and functional maintenance and repair of the central nervous system. It is also capable of promoting the regeneration of injured neurons in the peripheral nervous system, improving the pathology of neurons and protecting the nerves against hypoxia (lack of oxygen)/ischemia (lack of blood supply).

Nutrition Therapy

Occupational Therapy

Occupational therapy interventions focus on adapting the environment, modifying the task and teaching the skill, in order to increase participation in and performance of daily activities, particularly those that are meaningful to the patient with physical, mental, or cognitive disorders. Our Occupational Therapists also focus much of their work on identifying and eliminating environmental barriers to independence and participation in daily activities, similar to everyday life.

Physiotherapy

Physical therapy or physiotherapy (often abbreviated to PT) is a physical medicine and rehabilitation specialty that, by using mechanical force and movements, remediates impairments and promotes mobility, function, and quality of life through examination, diagnosis, prognosis, and physical intervention. We combine our PT with stem cells for maximum physical rehabilitation improvements.

Transcranial Magnetic Stimulation

Research has shown that TMS can effectively treat symptoms of depression, anxiety, neurological pain, stroke, spinal cord injuries, autism and more. This procedure is very simple and noninvasive. During the procedure, a magnetic field generator or coil is placed near the head of the person receiving the treatment. The coil produces small electrical currents in the region of the brain just under the coil via electromagnetic induction. This electrical field causes a change in the transmembrane current of the neuron which leads to depolarization or hyperpolarization of the neuron and the firing of an action potential.

Go here to see the original:
Stem Cell Treatments and Therapies from Beike Biotechnology

Read More...

Domestic policy of the George W. Bush administration …

Monday, January 28th, 2019

This article discusses the domestic policy of the George W. Bush administration.

Following the September 11 attacks, the Bush Administration proposed and Congress approved, a series of laws stated to be necessary in prosecuting the "War on Terror." These included a wide variety of surveillance programs, some of which came under heavy fire from civil liberties interest groups that criticized the new regulations for infringing upon certain civil liberties. The administration has also been criticized for refusing to back various security measures relating to port security in 2003 and 2004 and vetoing all US$39 million for the 2002 Container Security Initiative.

In early 2001, President Bush worked with Republicans in Congress to pass legislation changing the way the federal government regulated, taxed and funded charities and non-profit initiatives run by religious organizations. Although prior to the legislation it was possible for these organizations to receive federal assistance, the new legislation removed reporting requirements, which required the organizations to separate their charitable functions from their religious functions. Bush also created the White House Office of Faith Based and Community Initiatives.[1] Days into his first term, Bush announced his commitment to channeling more federal aid to faith-based service organizations. Bush created the Office of Faith-Based and Community Initiatives to assist faith-based service organizations. Critics claimed that this was an infringement of the separation of church and state.[2][3]

As Governor of Texas, Bush had opposed efforts to repeal the criminal prohibition on "homosexual conduct", the same law that the United States Supreme Court overturned in 2003, Lawrence v. Texas. During the 2000 campaign he did not endorse a single piece of gay rights legislation, although he did meet with an approved group of Log Cabin Republicans, a first for a Republican presidential candidate.[4]

In his first four years of office, his views on gay rights were often difficult to ascertain, but many experts feel that the Bush White House wanted to avoid bad publicity without alienating evangelical conservative Christian voters. Thus, he did not repeal President Clinton's Executive Order banning discrimination based on sexual orientation in the federal civilian government, but its critics felt it was ignored.[5] He did not attempt to repeal Don't ask, don't tell, nor try to change it. He threatened to veto the Matthew Shepard Act, which would have included sexual orientation in hate crimes.

While President Bush had always been on record as opposing the legal recognition of same-sex marriages, the 2004 Republican campaign strategy was to focus on "value issues" such as a Federal Marriage Amendment, that would prohibit same-sex couples from obtaining any legal recognition. President Bush endorsed this proposed amendment, but late in the campaign told ABC News and Larry King that he did not have a problem with state legislators enacting some type of civil unions legislation, although critics charged that the constitutional amendment he endorsed did not permit recognition of such unions.

Bush still expressed support for the Federal Marriage Amendment in his February 2, 2005 State of the Union addressand during the 2006 midterm election, but given that it did not even receive majority support in the Senate, has ignored this issue in his most recent public statements and speeches.

Bush was the first Republican president to appoint an openly gay man to serve in his administration, Scott Evertz, as director of the Office of National AIDS Policy.[6] In addition, during Bush's first term, his nominee as ambassador to Romania, Michael E. Guest, became the first openly gay man to be confirmed by the Senate as a U.S. ambassador. The first openly gay ambassador, James Hormel, received a recess appointment from Bill Clinton after the Senate failed to confirm the nomination.

According to a CNN exit poll, Bush's support from African-Americans increased during his presidency from 9% of the black vote in 2000 to 11% in 2004.[7] An increase in Ohio (from 9% to 16%,[7] each about 5%) may have helped give the victory to Bush over Kerry.

Although Bush expressed appreciation for the Supreme Court's ruling upholding the selection of college applicants for purposes of diversity, his Administration filed briefs against it. Bush has said he opposes government sanctioned and enforced quotas and racial preferences, but that the private and public sector should be encouraged to reach out to accomplished minorities to increase employment diversity.

In August 2005, a report by the United States Commission on Civil Rights states that "the government fails to seriously consider race-neutral alternatives as the Constitution requires."[8] Chairman Gerald A. Reynolds explained, "Federal agencies do not independently evaluate, conduct research, collect data, or periodically review programs to determine whether race-neutral strategies will provide an adequate alternative to race-conscious programs." Civil rights groups expressed concern that the report was an attack on affirmative action inconsistent with Grutter v. Bollinger.

In his first term, Bush appointed Colin Powell as Secretary of State. Powell was the first African-American man to serve in that position, and was succeeded by Condoleezza Rice: Rice became the first African-American woman to hold the post. In 2005, he appointed Alberto Gonzales as the United States Attorney General, the first Hispanic to hold that position.

Bush met with the National Urban League, the nation's oldest civil rights organization during his term of office as well.

President George W. Bush signed into law the Genetic Information Nondiscrimination Act (GINA).[9][10] The bill protects Americans against discrimination based on their genetic information when it comes to health insurance and employment. The issue had been debated for 13 years before becoming law. It is designed to protect citizens while not hindering genetic research.

On December 19, 2002, Bush signed into law H. R. 4664, far-reaching legislation to put the National Science Foundation (NSF) on a track to double its budget over five years and to create new mathematics and science education initiatives at both the pre-college and undergraduate level.[11] In the first three years of those five, the R&D budget has increased by fourteen percent.[12][13] Bush has long been dogged by criticism that his administration ignores or suppresses scientific advice.[14] Bush showed support for oceanography and space exploration; and supported sciences on reducing pollution. Bush generally was opposed to biology especially the science of human reproduction and reproductive health; and science with global warming. Bush supported "Teach the Controversy". Bush's positions were not always shared by his party.

President Bush supported adult stem cell research and umbilical cord blood stem cell research. However, Bush opposed any new embryonic stem cell research, and had limited the federal funding of existing research. Federal funding for embryonic stem cell research was first approved under President Clinton on January 19, 1999,[citation needed] but no money was to be spent until the guidelines were published. The guidelines were released under Clinton on August 23, 2000.[citation needed] They allowed use of unused frozen embryos. On August 9, 2001, before any funding was granted under these guidelines, Bush announced modifications to the guidelines to allow use of only existing stem cell lines.[15] While Bush claimed that more than 60 embryonic stem cell lines already existed from privately funded research, scientists in 2003 said there were only 11 usable lines, and in 2005 that all lines approved for Federal funding are contaminated and unusable.[16] Adult stem cell funding was not restricted and was supported by President Bush as a more viable means of research.

On January 14, 2004, Bush announced a Vision for Space Exploration,[17] calling for the completion of the International Space Station by 2010 and the retirement of the space shuttle while developing a new spacecraft called the Crew Exploration Vehicle under the title Project Constellation. The CEV would be used to return American astronauts to the Moon by 2018, with the objective of establishing a permanent lunar base, and eventually sending future manned missions to Mars.[18] To this end, the plan proposes that NASA's budget increase by five percent every year until it is capped at US$18 billion in 2008, with only inflationary increases thereafter.[19] The planned retirement of the Space Shuttle fleet in 2010 after the ISS is completed is also expected to free up US$5 billion to US$6 billion a year. The US$16.2 billion budget for 2005 proposed by NASA met with resistance from House and Senate spending committees, and the initiative was little-mentioned during the presidential campaign.[20] Nonetheless, the budget was approved with only minor changes shortly after the November elections.

Supporters believe that this plan will be an important part of what Bush set in place while in office. However, the policy has been criticized on two fronts. Firstly, critics have opined that the United States should deal with solving domestic issues before concentrating on space exploration. Secondly, of the funding over the next five years that Bush has proposed, only US$1 billion will be in new appropriations while the remaining US$11 billion will be reallocated from NASA's other programs, and therefore inadequate to fully realize this vision. Most of the spending for the new program, and most of the budget cuts for existing programs, are scheduled after the last year of the Bush presidency. It is unclear how the space vision will be reconciled with budgetary concerns in the longer term.

In January 2005, the White House released a new Space Transportation Policy fact sheet[21] which outlined the administration's space policy in broad terms and tied the development of space transport capabilities to national security requirements.

In December 2003, Bush signed legislation implementing key provisions of his Healthy Forests Initiative. Another subject of controversy is Bush's Clear Skies Initiative, which seeks to reduce air pollution through expansion of emissions trading.

Bush signed the Great Lakes Legacy Act of 2002 authorizing the federal government to begin cleaning up pollution and contaminated sediment in the Great Lakes, as well as the Brownfields Legislation in 2002, accelerating the cleanup of abandoned industrial sites, or brownfields, to better protect public health, create jobs, and revitalize communities.

Bush stated his reason for not supporting the Kyoto Protocol was that it unfairly targeted the United States while being deliberately lenient with certain developing countries, especially China and India. Bush stated, "The world's second-largest emitter of greenhouse gases is China. Yet, China was entirely exempted from the requirements of the Kyoto Protocol."

Bush also questioned the science behind the global warming phenomenon, insisting that more research be done to determine its validity.[22]

Upon arriving in office in 2001, President Bush withdrew United States support of the then-pending Kyoto Protocol, a UN Convention seeking to impose mandatory targets for reducing "greenhouse gas" emissions. Bush stated that human activity had not been proven to be the cause and cited concerns about the treaty's impact on the U.S. economy and pointed out that China and India had not signed on.[23] The Protocol entered into force on 16 February 2005. As of September 2011, 191 states have signed and ratified the protocol.[24] The only remaining signatory not to have ratified the protocol is the United States.

In 2002, the Bush Administration's EPA issued a Climate Action Report concluding that the climate changes observed over several decades "are likely mostly due to human activities, but we cannot rule out that some significant part of these changes is also a reflection of natural variability".[25] While the EPA report was initially hailed by some environmentalists critical of the Bush administration as a "180-degree turn on the science" reversing "everything the president has said about global warming since he took office," within days President Bush dismissed the report as being "put out by the bureaucracy," and reaffirmed his opposition to the Kyoto Protocol.[25]

The Bush Administration's stance on global warming, and in particular its questioning the consensus of scientists, would remain controversial in the scientific and environmental communities during his presidency. In 2004, the Director of NASA's Goddard Institute, James E. Hansen, came out publicly and harshly accusing the Administration of misinforming the public by suppressing the scientific evidence of the dangers of greenhouse gases, saying the Bush Administration wanted to hear only scientific results that "fit predetermined, inflexible positions" and edited reports to make the dangers sound less threatening in what he asserted was "direct opposition to the most fundamental precepts of science."[26][27] Other experts, such as former U.S. Department of Energy official Joseph Romm, have decried the Bush administration as a "denier and delayer" of government action essential to reduce carbon emissions and deter global warming.[28]

In 2005, Council on Environmental Quality chairman and former oil industry lobbyist Philip Cooney, was accused of doctoring and watering down descriptions of climate research from other government agencies. The White House denied these reports.[29] Two days later, Cooney announced his resignation[30] and conceded his role in altering the reports. "My sole loyalty was to the President and advancing the policies of his administration," he told the United States House Committee on Oversight and Government Reform.[31][32]

In addition, the administration thanked Exxon executives for the company's "active involvement" in helping to determine climate change policy, including the US stance on Kyoto.[33]

President Bush believes that global warming is real[34] and has said that he has consistently noted that global warming is a serious problem but asserted there is a "debate over whether it's manmade or naturally caused" and maintained that regardless of that debate his administration was working on plans to make America less dependent on foreign oil "for economic and national security reasons."[35]

The United States has signed the Asia Pacific Partnership on Clean Development and Climate, a pact that allows signatory countries to set goals for reducing greenhouse gas emissions individually, but with no enforcement mechanism. Republican Governor Arnold Schwarzenegger, along with 187 mayors from US towns and cities, have pledged to adopt Kyoto style legal limits on greenhouse gas emissions.[36]

For economic and national security reasons, Bush supported Alaska Senator Ted Stevens' plan to tap the oil reserves in a 2,000-acre (8km2) area of Alaska's 19 million acre (77,000km) Arctic National Wildlife Refuge. Pro-exploration supporters argue that U.S. companies have the most stringent environmental requirements, and that by doing the drilling in the middle of the winter, it would create a very small environmental footprint.[37]

Opponents stated that drilling would damage the coastal plain's fragile ecosystem and its wildlife. Proponents stated that modern techniques can extract the oil without damaging the environment [38]

Initially announced by President Bush in 2002,[39] the Clear Skies Initiative was aimed at amending the Clean Air Act to further reduce air pollution and expanded the emissions trading programs to include new pollutants such as mercury. The goal of the initiative was to reduce the sulfur dioxide, nitrogen oxide, and mercury emissions of power plants over the course of 15 years, while saving consumers millions of dollars.[39]

Among other things, the Clear Skies Act states that it would:[40][41][42]

The Natural Resources Defense Council, and its more than 500,000 members, examined the administration proposal and concluded it would harm public health, weaken current pollution fighting programs and worsen global warming. S. 385, the administration's bill to amend the Clean Air Act would:1. Allow power plant pollution to continue to inflict huge, avoidable health damages on the public. 2. Repeal or interfere with major health and air quality safeguards in current law. 3. Worsen global warming by ignoring CO2 emissions from the power sector.[43]

In January 2002, Bush signed the No Child Left Behind Act, with Democratic Senator Ted Kennedy as chief sponsor,[44] which aims to close the achievement gap, measures student performance, provides options to parents with children in low-performing schools, and targets more federal funding to low-income schools. Critics, including Senator John Kerry and the National Education Association, say schools were not given the resources to help meet new standards, although their argument is based on premise that authorization levels are spending promises instead of spending caps. The House Committee on Education and the Workforce said that the Department of Education's overall funding increased by US$14 billion since the enactment of NCLB in fiscal year 2001, going from US$42.6 billion to US$56.6 billion in fiscal year 2005.[citation needed] Some state governments are refusing to implement provisions of the act as long as they are not adequately funded.[45]

In January 2005, USA Today reported that the United States Department of Education had paid US$240,000 to African-American conservative political commentator Armstrong Williams "to promote the law on his nationally syndicated television show and to urge other black journalist to do the same."[46] Williams did not disclose the payments.

The House Education and Workforce Committee stated, "As a result of the No Child Left Behind Act, signed by Bush on January 8, 2002, the Federal government today is spending more money on elementary and High School (K-12) education than at any other time in the history of the United States.[citation needed] Funding increases have to a large degree been offset at the state level by increased costs associated with implementing NCLB, as well as the impacts of the economic downturn on education budgets.

According to the National Bureau of Economic Research, the economy suffered from a recession that lasted from March 2001 to November 2001. During the Bush Administration, Real GDP has grown at an average annual rate of 2.5%.[47]

Inflation under Bush has remained near historic lows at about 2-3% per year. The recession and a drop in some prices led to concern about deflation from mid-2001 to late 2003. More recently, high oil prices have caused concern about increasing inflation.

Long-term problems include inadequate investment in economic infrastructure, rapidly rising medical and pension costs of an aging population, sizable trade and budget deficits. Under the Bush administration, productivity has grown by an average of 3.76% per year, the highest such average in ten years.[48]

While the GDP recovered from a recession that some claim Bush inherited from the previous administration,[49] poverty has since worsened according to the Census Bureau. The percentage of the population below the poverty level increased in each of Bush's first four years, while it decreased for each of the prior seven years to an 11-year low. Although the poverty level increased the increase was still lower from 2000 to 2002 than it was from 1992 to 1997, which reached a peak of 39.3% in 1993. In 2002 the poverty rate was 34.6% which was almost equal to the rate in 1998, which was 34.5%. Poverty was at 12.7% in 2004.[citation needed]

President Bush won passage for two major tax cuts during his term in office: The Economic Growth and Tax Relief Reconciliation Act of 2001 and the Jobs and Growth Tax Relief Reconciliation Act of 2003. Collectively, they became known, analyzed, and debated as the "Bush tax cuts".

The cuts, scheduled to expire a decade after passage, increased the standard income tax deduction for married couples, eliminated the estate tax, and reduced marginal tax rates. Bush asked Congress to make the tax cuts permanent, but others wanted the cuts to be wholly or partially repealed even before their scheduled expiration, seeing the decrease in revenue while increasing spending as fiscally irresponsible.

Bush's supporters claim that the tax cuts increase the pace of economic recovery and job creation. They also claim that total benefits to wealthier individuals are a reflection of higher taxes paid. Individual income tax rate provisions in the 2001 law, for instance, created larger marginal tax rate decreases for people earning less than US$12,000 than any other earners.[50]

His opponents contest job prediction claims, primarily noting that the increase in job creation predicted by Bush's plan failed to materialize. They instead allege that the purpose of the tax cuts was intended to favor the wealthy and special interests, as the majority of benefit from the tax cut, in absolute terms, went to earners in the higher tax brackets. Bush's opponents additionally claim that the tax cuts are a major reason Bush reversed a national surplus into a historically large deficit.

In an open letter to Bush in 2004, more than 100 professors of business and economics at U.S. business schools ascribed this "fiscal reversal" to Bush's "policy of slashing taxes - primarily for those at the upper reaches of the income distribution."[51]

By 2004, these cuts had reduced federal tax revenues, as a percentage of the Gross Domestic Product, to the lowest level since 1959. With the NASDAQ crash and one quarter of negative growth in 2000 it was likely we were headed into a recession,[52] yet merely two years after the 2003 Bush tax cuts, federal revenues (in dollars) had reached a record high.[53] The effect of simultaneous record increases in spending and tax reductions was to create record budget deficits in absolute terms, though as recently as 1993, the deficit was slightly larger than the current 3.6% of the GDP. In the last year of the Clinton administration, the federal budget showed an annual surplus of more than US$230 billion.[54] Under Bush, the government returned to deficit spending. The annual deficit reached an absolute record of US$374 billion in 2003 and then a further record of $413 billion in 2004.[55][56]

President Bush expanded public spending by 70 percent, more than double the increase under President Clinton. Bush was the first president in 176 years to continue an entire term without vetoing any legislation.[57]

The tax cuts, recession, and increases in outlays all contributed to record budget deficits during the Bush administration. The annual deficit reached record current-dollar levels of US$374 billion in 2003 and US$413 billion in 2004. National debt, the cumulative total of yearly deficits, rose from US$5.7 trillion (58% of GDP) to US$8.3 trillion (67% of GDP) under Bush,[citation needed] as compared to the US$2.7 trillion total debt owed when Ronald Reagan left office, which was 52% of the GDP.[58]

According to the "baseline" forecast of federal revenue and spending by the Congressional Budget Office (in its January 2005 Baseline Budget Projections),[59] the budget deficits will decrease over the next several years. In this projection the deficit will fall to US$368 billion in 2005, US$261 billion in 2007, and US$207 billion in 2009, with a small surplus by 2012. The CBO noted, however, that this projection "omits a significant amount of spending that will occur this year and possibly for some time to come for U.S. military operations in Iraq and Afghanistan and for other activities related to the global War on Terrorism." The projection also assumes that the Bush tax cuts "will expire as scheduled on December 31, 2010." If, as Bush has urged, the tax cuts were to be extended, then "the budget outlook for 2015 would change from a surplus of US$141 billion to a deficit of US$282 billion." Other economists have disputed this, arguing that the CBO does not use dynamic scoring, to take into account what effect tax cuts would have on the economy.

Federal spending in constant dollars increased under Bush by 26% in his first four and a half years. Non-defense spending increased 18% in that time.[60] Of the US$2.4 trillion budgeted for 2005, about US$450 billion are planned to be spent on defense. This level is generally comparable to the defense spending during the cold war.[citation needed] Congress approved US$87 billion for Iraq and Afghanistan in November, and had approved an earlier US$79 billion package last spring. Most of those funds were for U.S. military operations in the two countries.

Former President Clinton's last budget featured an increase of 16% on domestic non security discretionary spending. Growth under President Bush was cut to 6.2% in his first budget, 5.5% in his second, 4.3% in his third, and 2.2% in his fourth.

Bush supports free trade policies and legislation but has resorted to protectionist policies on occasion. Tariffs on imported steel imposed by the White House in March 2002 were lifted after the World Trade Organization ruled them illegal. Bush explained that the safeguard measures had "achieved their purpose", and "as a result of changed economic circumstances", it was time to lift them.[61]

President Bush signed a large number of free trade agreements into law during his Presidency: Jordan (2001), Singapore and Chile (2004), Australia (2005), Dominican Republic, CAFTA, Morocco, Oman, and Bahrain (2006), and Oman and Peru (2009).

The Bush administration also launched trade negotiations with New Zealand, Thailand, Kuwait, Malaysia, Qatar, South Korea, Colombia, and Panama, with some being completed during President Obama's first term in office (2009-2013).

Some say economic regulation expanded rapidly during the Bush administration. President Bush is described by these observers as the biggest regulator since President Richard Nixon.[62] Bush administration increased the number of new pages in the Federal Registry, a proxy for economic regulation, from 64,438 new pages in 2001 to 78,090 in new pages in 2007, a record amount of regulation.[62] Economically significant regulations, defined as regulations which cost more than $100 million a year, increased by 70%.[62]

Spending on regulation increased by 62% from $26.4 billion to $42.7 billion.[62]

The contrary view on Bush's regulatory record is that he discouraged regulators from enforcing regulations and that counting pages in the Federal Register is a myopic method of measuring an administration's regulatory stance. The 2008 financial crisis occurred near the end of the Bush second term and represented an enormous failure for financial deregulation.[63]

Looking at the annual average unemployment rates for each of the eight years of Bush's presidency, the average of all eight figures, and thus of his entire presidency, is 5.26%, with a low of 4.6% for the years of 2006 and 2007, and a high of 6.0% for 2003.[64]

According to the Bureau of Labor Statistics, the number of unemployed was nearly 6.0 million in January 2001 and 6.9 million in September 2006. The unemployment rate was 4.2% in January 2001, 4.6% in September 2006, and 7.2% in December 2008. Employment peaked in late 1999 and declined through 2008.[65]

The Current Population Survey (aka Household Survey) measures the percentage of the population that is employed and unemployed. The result can be multiplied by population estimates to get total employment estimates. This survey has the advantage over the payroll survey in that it includes self-employed. The Household Survey is less accurate in producing total numbers since it requires population estimates and in that it samples many fewer people (60,000 households versus 400,000 business establishments). For better or worse, the Household Survey counts multiple jobs held by one person only once, and it includes government workers, farm workers, unpaid family workers, and workers absent without pay. The Household Survey indicates that the percentage of the population employed decreased from 64.4% in December 2000 and January 2001 to 62.1% in August and September 2003. By August 2005, it had recovered only to 62.9%. In absolute numbers, this corresponds to a drop of 1.6 million jobs but an eventual net gain of 4.7 million jobs during the Bush administration.[66]Private sector employment, as measured by private nonfarm payrolls, shrank over the 8 years of the George W. Bush presidency. There were modest gains in private-sector payroll employment during his first term, but these were more than offset by the shedding of workers by the private sector in his second term. There were 463,000 fewer private-sector payroll jobs when he left office than when he came into office.[67]

In 2004, a full chapter on Iraq's economy was excised from the Economic Report of the President, in part because it doesn't fit the "feel good" tone of the writing, according to White House officials.[citation needed]

In July 2002, Bush cut off U.S. funding to the United Nations Population Fund (UNFPA). Bush stated that the UNFPA supported forced abortions and sterilizations in the People's Republic of China.[68]

Bush signed the Medicare Act of 2003, which added prescription drug coverage to Medicare (United States), subsidized pharmaceutical corporations, and prohibited the Federal government from negotiating discounts with drug companies.

Bush signed the Partial-Birth Abortion Ban Act in 2003, having declared his aim to "promote a culture of life".

Bush is an advocate of the partial privatization of Social Security wherein an individual would be free to invest a portion of his Social Security taxes in personal retirement accounts.

Bush has called for major changes in Social Security, identifying the system's projected insolvency as a priority early in his second term. From January through April 2005, he toured the country, stopping in over 50 cities across the nation warning of an impending "crisis". Initially, President Bush emphasized his proposal for personalized accounts would allow individual workers to invest a portion of their Social Security Tax (FICA) into secured investments. The main advantage of personal accounts within Social Security is to allow workers to own the money they place into retirement that cannot be taken away by political whims.

Most Democrats and some Republicans are critical of such ideas, partly because of the large (US$1 trillion or more) federal borrowing the plan would require, which might actually worsen the imbalance between revenues and expenses that Bush pointed to as a looming problem; and partly because of the problems encountered by the United Kingdom's privatized pension plan. See Social Security debate (United States). In addition, many Democrats opposed changes that they felt were turning Social Security into a welfare program that would be politically vulnerable. Portions of Bush's bill exempting private companies from social security payments have led to complaints that Bush's plan was created to benefit private companies, and that it would turn Social Security into just another insurance program.

George W. Bush is a strong supporter of capital punishment. During his tenure as Governor of Texas, 152 people were executed in that state, maintaining its record as the leading state in executions.[69] As President of the United States, he has continued in his support for capital punishment, including presiding over the first federal execution in decades, that of convicted terrorist Timothy McVeigh. Although Bush's support of the death penalty is known, controversy broke in 1999 when journalist Tucker Carlson revealed that the Governor had mocked the plight of Karla Faye Tucker in an interview.

On his first day in office, President Bush implemented the Mexico City Policy; this policy required nongovernmental organizations receiving federal funds to agree not to perform abortions or to actively promote abortion as a method of family planning in other nations.[70][71] In 2002, President Bush signed the Born-Alive Infants Protection Act, which extends legal protection to infants born alive after failed attempts at induced abortion.[72] Also in 2002, President Bush withdrew funding from the United Nations Population Fund based on a finding that UNPF's activities facilitated China's one-child-only/forced abortion policy.[73] In 2003, President Bush signed the Partial Birth Abortion Ban Act into law;[74] that law was later upheld by the Supreme Court of the United States in Gonzales v. Carhart.[75] President Bush signed the Unborn Victims of Violence Act (Laci and Conner's Law), which provides that a person who commits certain federal violent crimes and thereby causes the death of, or bodily injury to, a fetus shall be guilty of a separate offense, whether or not the person knew the mother was pregnant or intended to harm the fetus.[76]

Bush staunchly opposes euthanasia. He supported Ashcroft's decision to file suit against the voter-approved Oregon Death with Dignity Act, which was ultimately decided by the Supreme Court in favor of the Oregon law.[77] As governor of Texas, however, Bush had signed a law which gave hospitals the authority to take terminally ill patients off of life support against the wishes of their spouse or parents, if the doctors deemed it medically appropriate.[78] This became an issue in 2005, when the President signed controversial legislation forwarded and voted on by only three members of the Senate to initiate federal intervention in the Terri Schiavo case.[79]

Bush signed the Amber Alert legislation into law on April 30, 2003, which was developed to quickly alert the general public about child abductions using various media sources.[80] On July 27, 2006 Bush signed the Adam Walsh Child Protection and Safety Act which establishes a national database requiring all convicted sex offenders to register their current residency and related details on a monthly instead of the previous yearly basis. Newly convicted sex offenders will also face longer mandatory incarceration periods.[81]

On June 15, 2006, Bush created the seventy-fifth, and largest, National Monument in U.S. history and the largest Marine Protected Area in the world with the formation of the Northwestern Hawaiian Islands National Monument.[82]

The Prison Rape Elimination Act of 2003 (PREA) is the first United States federal law passed dealing with the sexual assault of prisoners. The bill was signed into law on September 4, 2003. As a result, the National Prison Rape Elimination Commission was created to study the problem and recommend solutions. Federal funding for prisons also began to require detainment facilities to keep records on sexual assault. Failure to follow PREA requirements resulted in losing up to 5% of funding. New grants to prevent sexual assault were also created by the law. Significant support for the act came from Human Rights Watch, Concerned Women for America, Just Detention International, and numerous evangelical organizations.

In 2005-06, Bush emphasized the need for comprehensive energy reform and proposed increased funding for research and development of renewable sources of energy such as hydrogen power, nuclear power, ethanol, and clean coal technologies. Bush proposed the American Competitiveness Initiative which seeks to support increasing competitiveness of the U.S. economy, with greater development of advanced technologies, as well as greater education and support for American students. In the 2007 State of the Union speech, President Bush proposed a 20:10 policy, where, as a nation, the United States would be working to reduce 20% of the national energy usage in next 10 years by converting to ethanol.

Bush's imposition of a tariff on imported steel and on Canadian softwood lumber was controversial in light of his advocacy of free market policies in other areas. The steel tariff was later rescinded under pressure from the World Trade Organization. A negotiated settlement to the softwood lumber dispute was reached in April 2006, and the historic seven-year deal was finalized on July 1, 2006.[citation needed]

Go here to see the original:
Domestic policy of the George W. Bush administration ...

Read More...

Neil Riordan PhD – Medistem Panama

Sunday, January 13th, 2019

Neil Riordan, PhD is the founder and chairman of Medistem Panama, Inc., (MPI) a leading stem cell laboratory and research facility located in the Technology Park at the prestigious City of Knowledge in Panama City, Panama. Founded in 2007, MPI stands at the forefront of applied research on adult stem cells for several chronic diseases. MPIs stem cell laboratory is ISO 9001 certified and fully licensed by the Panamanian Ministry of Health. Dr. Riordan is the founder of Stem Cell Institute (SCI) in Panama City, Panama (est. 2007).

Under the umbrella of MPI subsidiary Translational Biosciences, MPI and SCI are currently conducting five IRB-approved clinical trials in Panama for multiple sclerosis, rheumatoid arthritis and osteoarthritis using human umbilical cord-derived mesenchymal stem cells, mesenchymal trophic factors and stromal vascular fraction. Additional trials for spinal cord injury, autism and cerebral palsy are slated to commence in 2014 upon IRB approval.

Dr. Riordans research team collaborates with a number of universities and institutions, including National Institutes of Health, Indiana University, University of California, San Diego, University of Utah, University of Western Ontario, and University of Nebraska.

Dr. Riordan has published over 60 scientific articles in international peer-reviewed journals and authored two book chapters on the use of non-controversial stem cells from placenta and umbilical cord. In the stem cell arena, he and his colleagues have published more than 20 articles on Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis, Duchenne Muscular Dystrophy, Autism, and Charcot Marie Tooth Syndrome. In 2007, Dr. Riordans research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery, his team was honored with the Medical Article of the Year Award from Biomed Central. Other notable journals in which Dr. Riordan has published articles include the British Journal of Cancer, Cellular Immunology, Journal of Immunotherapy, and Translational Medicine.

Dr. Riordan is an accomplished inventor; listed on more the 25 patent families, including 11 issued patents. He is credited with a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father Dr. Hugh Riordan on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin Cs preferential toxicity to cancer cells notably led to a 1997 patent grant for the treatment of cancer with vitamin C. In 2010, Dr. Riordan received another patent for a new cellular cancer vaccine.

Dr. Riordan is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals including Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.

Dr. Riordan earned his Bachelor of Science at Wichita State University and graduated magna cum laude. He received his Masters degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the America

Continued here:
Neil Riordan PhD - Medistem Panama

Read More...

Nobel Prize Doctor Yamanaka: Stem Cell Progress ‘Just the …

Saturday, November 17th, 2018

Professor Shinya Yamanaka of Kyoto University, 55, became more widely known after he was awarded the Nobel Prize in Physiology or Medicine in 2012. Five years before that, however, in November 2007, he announced that he had generated human-induced pluripotent stem cells (iPS cells).

His research on treating illnesses has seen impressive progress, but, according to him, this is just the beginning.

Yamanaka, 55, was born in 1962 in Osaka. He graduated from Kobe University School of Medicine and completed his PhD at Osaka University Graduate School. He became a professor at Kyoto University in 2004 and the director of Center for iPS Cell Research and Application in 2010.

He recently spoke with journalist Juichiro Ito of Sankei Shimbuns Science Department about the future of medical treatment through iPS cell generation.

Its the 10th anniversary of human iPS cell generation.

It sounds like a long time, but it feels like yesterday. I cant believe it has been that long. Maybe time flies faster for me because Im old now, but this is only the beginning.

Research on regenerative medicine and clinical trials of new drugs have begun.

iPS cells have been a catalyst to research that use embryonic stem cells (ES cells). I cannot take all the credit because I wouldnt have made it this far without the efforts of everyone involved. I always remind myself how grateful I should be. Clinical research on age-related macular degeneration (AMD) led by Masayo Takahashi of Riken research institute impressed me the most. By skipping the preclinical development stage consisting of animal testing, she managed to make significant accomplishments in a very short period.

What was the challenge?

The challenge was to build an iPS cell stock which ensures that iPS cells will always be available for regenerative medicine and drug discovery. The process involves providing cells to a specialized company for mass production, which then supplies the cells to medical institutes and pharmaceutical companies. It was a very difficult process because university researchers are a type of people who want to challenge themselves with the unprecedented. Conversely, the production of cells requires the dull repetition of prescribed steps in order to maintain quality. Dealing with this contrast was very difficult.

At first, people pointed out the risks of the cells becoming cancerous.

The early-stage iPS cells couldnt be used for clinical research because of these concerns. However, the production method has evolved and the situation has changed. The risk has not been completely eliminated but is significantly lower, so the cells can now be used for clinical research.

You were awarded the Nobel Prize in Physiology or Medicine in 2012.

It was a great honor. The moment I successfully generated iPS cells, I had the huge responsibility of getting things off the ground, starting with the clinical research. But receiving the prize increased awareness within the general public and those in the industry, and this became a tailwind for my research in many ways. Im very grateful for that, as it also helped Kyoto University collect funds for the Center for iPS Cell Research Application (CiRA).

If you were to compare the current iPS research to a marathon, how many kilometers do you still have to run?

It might be an exaggeration to say that were only at the start line, but I would say weve run no more than 10 kilometers. The real challengethe crucial stagesstarts now, including clinical research and trials of new drugs. Our goal is truly ambitious, as we are taking unprecedented steps while prioritizing the safety of the patients. Im assuming that the challenges that lie ahead will be incomparable to anything Ive faced in the past.

What is the goal of the research?

I estimate that several treatments using regenerative medicine and new drugs will be developed, authorized, and covered by insurance around 2030. However, some treatments may take longer to develop, and unforeseeable challenges may come up. We cannot simply visualize our goal. Its more important to take slow but sure steps towards it.

What are the problems regarding cost and time?

In regenerative medicine, it takes a lot of money and time to custom-make iPS cells from the patients cells. Instead, we create iPS cells from dozens of people with an immunological type that has a lower risk of rejection in Japanese people. However, the great hurdle is how to maintain ample stock of these cells.

What percentage of the population do the cells cover?

Currently, we provide iPS cells of three immunological types. They will not trigger a rejection response in 30% of the Japanese population. It shouldnt be long until we reach 50%. However, we are concerned that increasing the types of iPS cells available will inevitably lead to a higher production cost, which means the cells might become difficult to access for medical treatment. The more cell types there are, the more production facilities the manufacturing companies will require, and more money and time will be necessary for safety checks. Alternatively, it might be more efficient to use just one type of cell which covers the greatest percentage of the population, and to provide immunosuppressant drugs to those that have a rejection response.

What is your plan for the future?

If a huge amount of national expenditure is invested into creating more types of cells but the cells end up being unusable, it would be a considerable waste. Until now, we have been aiming to reach 80% of the population by 2022, but we are now reevaluating our goal. This is a problem we cannot solve by ourselves. We want the government to consider implementing a system that ensures safety checks while containing the costs.

Clinical research and trials have started to make the cells useful for patients.

We have only just reached the start line. For the next 10 or 20 years, it will be more like the patients contributing to the research at their own risk, rather than us contributing to them. I need to start making true contributions to the patients as soon as possible. People enduring incurable diseases have written numerous letters to us about their wish to be cured using iPS cells. I am fully aware of their desperate situation and working hard towards making their wish come true.

Ikumi Yamamoto, 19, from Akashi in Hyogo Prefecture, who suffered from fibrodysplasia ossificans progressiva (FOP), underwent the first ever treatment for incurable diseases using iPS cells in October.

She came to see me when she was a sixth grade elementary student, and told me that she wanted me to generate iPS cells using her cells to further my research. Such encounters have become a driving force in my research. I think of iPS cells as the patients themselves. When I conduct experiments, the face of the patients who provided the original cells always come to my mind, which makes me more determined to find a cure for them.

Hideo Shinozawa, an honorary professor of Gakushuin University, died in October after a long battle with amyotrophic lateral sclerosis (ALS).

The professor sent me a letter to tell me how much he wanted me to develop a treatment. The letter is displayed in my laboratory so that I am always reminded of his strong desire while I go about my work. ALS is one of the diseases I want to defeat the most. I want to find a cure as soon as possible, but Im unfortunately not at that stage yet.

What kind of attitude should medical researchers have?

As a researcher, you must first conduct good research and write research papers. While doing this, the researcher must have a strong determination to help the patients no matter how long it takes. Being a researcher is difficult, but thinking about the patients keeps us going.

Do you still run marathons as a hobby?

During my lunch breaks on weekdays, I run for 30 minutes along Kamo River and near Nanzen-ji Temple, which are located near the research institute. On weekends, I run around Osaka Castle near my house and around the Tokyo Imperial Palace when Im in Tokyo for work. Running helps me refresh my tired brain, just like the initialization process involved in iPS cell generation.

I managed to run a personal best of 3 hours 27 minutes and 42 seconds at the Kyoto Marathon in February. I will run the Osaka Marathon in November. The Beppu-ita Marathon, which I will be running next February, will be used to select representatives for the 2020 Tokyo Olympics, so I might have a chance. Perhaps well see a miracle (laughs).

The Rapid Progress of Clinical Research and the Challenge of Efficient Cell Generation

iPS cell research has garnered attention as people put their hopes on regenerative medicine to transplant new cells and tissue to injured or ill patients. Research institute Riken succeeded in the first ever transplant in 2014 using iPS cells, setting a major landmark in this field.

The transplant involved creating retinal cells using iPS cells generated from a patient with age-related macular degeneration, a serious eye condition. In March 2017, the transplant of retinal cells from a donor using stock iPS cells succeeded, totalling five successful transplants.

For 2018, clinical research on spinal cord injury and heart failure are being scheduled by Keio University and Osaka University, respectively. Yokohama City University also plans to conduct clinical research on liver failure in 2019 onwards, making Japan the trail blazer in this area. However, most of this research is on cell transplantation; the possibility of transplanting complex organs is still not within reach.

iPS cells are also used to research the pathogenesis of diseases and drug discovery. This is because the mechanisms of diseases can be revealed by creating iPS cells from patients with incurable diseases and replicating the disease outside of the body. Recently, the mechanisms of diseases that affect the motor system, such as Parkinsons disease and ALS, have become better understood.

The mass production of the patients cells for testing makes the development of new drugs more efficient. Potential treatment for FOP, a disease that turns muscle into bone, has been discovered through this method. The method is also being used for ALS and Alzheimers disease. However, this method has not met early expectations that it would be available for clinical application sooner than regenerative medicine.

The big challenge is efficient cell generation. It takes several months to create iPS cells and cells of the affected area. Research on implementing artificial intelligence for efficiency and improvement of cell generation methods is intensifying.

Juichiro Ito is a staff writer of the Sankei Shimbun Science news department.

See the rest here:
Nobel Prize Doctor Yamanaka: Stem Cell Progress 'Just the ...

Read More...

Crowdfunding to have an advanced Stem cell treatment in …

Thursday, October 18th, 2018

Thank you for opening my page. I am 34 years old and can only travel short distances with a walking stick due to my worsening condition. MS is caused by the immune system attacking the nervous system and causes many dibilitating symptoms. I am desperately raising money for this treatment to halt and repair the damage so I can lead a normal life and start to plan for my future.....please take a moment to hear my story.

Throughout 2013 I had many visits to my Doctors to discuss my worsening symptoms that were causing concern. On every occasion I visited the GP I was dismissed and misdiagnosed. In February 2014 I collapsed and was immediately rushed to hospital, as I could not see or walk. My girlfriend and I who had only been together weeks had our dreams shattered, we knew things were going to get tough but this has been gruelling. I have had to relearn to walk and I have never fully regained my vision.

Four years since my diagnosis and it is like living a nightmare. My symptoms have grown significantly worse, medication available on the NHS, changes to my diet, holistic treatments and supplements have made little difference. My symptoms have meant that I have been forced to reduce my working hours and I am increasingly house-bound. There is currently no cure for this on the NHS. There are successful trials being undertaken by Cambridge University but with the speed and the progression of my illness I dont have the time to wait before my condition worsens. This is why I am asking for your help, even the smallest of donations will go a very long way. I am totally grateful to my family and friends who are all undertaking fund raising events on my behalf. The fight is hard but I will not be defeated. I will be eternally thankful for any time, effort and money put towards this cause. This treatment could make such an improvement to my life.

Any money raised over my target will be donated to similar causes. Thanks again for reading.

Liam x

Link:
Crowdfunding to have an advanced Stem cell treatment in ...

Read More...

Page 3«..2345..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick